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Gastric cancer (GC) is the second leading cause of cancer death worldwide. Despite 
declining incidence rates globally, the overall five year survival rate of GC is less than 
24%, which is much lower compared to other cancers. Early stage stomach cancer is 
often difficult to diagnose because of nonspecific symptoms. Therefore, understanding 
the pathogenesis and biological features, as well as identification of new markers and 
therapeutic targets of GC are crucial to improve its detection and therapy. 
 
Like many other cancers, chromosomal instability is frequently observed in GC. Detailed 
characterization of the aberrant regions in cancer has identified several potential 
oncogenes and tumor suppressor genes that may contribute to carcinogenesis. 
.
Among the 
various genomic abnormalities associated with cancers, fusion genes and transcripts are 
particularly notable due to their cancer-specific nature and their translational potential as 
diagnostic and therapeutic targets. Although previously largely restricted to hematologic 
malignancies, recent studies have shown that fusion genes in solid epithelial tumors can 
also be elucidated using high-resolution genomic approaches. For example, TMPRSS2-
ERG was identified in prostate cancer and EML4-ALK in non-small-cell lung cancer.  
 
Therefore, using detailed fine-scale survey of genomic copy number alterations (CNAs), 
our objective is to identify possible fusion transcripts in GC which may provide further 
mechanistic insights into GC development and highlight opportunities for early detection 





We profiled a discovery cohort of 133 GCs (106 primary tumors and 27 cell lines) using 
high density array-based comparative genomic hybridization (aCGH) microarrays. To 
nominate potential fusion genes, we used a technique called genomic breakpoint analysis 
(GBA), previously used to identify fusion genes in leukemia. With this strategy, we 
discovered several tumors exhibiting recurrent genomic breakpoints in the 
SLC1A2/EAAT2 gene, encoding a glutamate transporter. Subsequent 5' RNA ligase 
mediated rapid amplification of cDNA ends (RLM-RACE) analysis of a GC cell line 
with SLC1A2 breakpoints (SNU16) revealed the expression of a CD44-SLC1A2 fusion 
transcript caused by a paracentric chromosomal inversion, which produced a truncated 
but functional SLC1A2 protein. Using custom-designed fusion-specific siRNAs, we 
showed that silencing of CD44-SLC1A2 in fusion-positive SNU16 cells significantly 
reduced cellular proliferation, invasion, and colony formation, but not in cell lines 
lacking CD44-SLC1A2 expression.  Conversely, CD44-SLC1A2 overexpression in gastric 
cells stimulated these pro-oncogenic traits. In addition, CD44-SLC1A2 silencing also 
significantly reduced intracellular glutamate levels and sensitized SNU16 cells to 
cisplatin, a commonly used chemotherapeutic agent in GC.  
 
We further demonstrated that recurrent CD44-SLC1A2 fusions were observed in primary 
gastric tumors. Although CD44-SLC1A2 expression was relatively rare in unselected GCs 
(2/43), the percentage of tumors testing positive for the CD44-SLC1A2 fusion was 
markedly increased when we screened GCs preselected for high SLC1A2 expression. In 
addition, we also found that genes upregulated in SLC1A2-high expressing tumors were 




supporting the notion that SLC1A2-high expressing tumors comprise a distinct molecular 
subclass. 
  
In conclusion, our study contributes not only to the identification of a recurrent novel 
fusion gene candidate in GC, which contributes to GC development and plays a role in 
cancer metabolism, but also suggests CD44-SLC1A2 may be a potential diagnostic 
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Identification of TMPRSS2:ETV1 and TMPRSS2:ERG gene 
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CD44-SLC1A2 silencing by fusion-specific siRNA1 inhibits 
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Chapter I: Introduction 
  
 




Gastric adenocarcinoma, or gastric cancer (GC) is a very common disease worldwide and 
the second most frequent cause of cancer death, affecting about one million people per 
year (Hartgrink et al., 2009). The geographical distribution of stomach cancer is 
characterized by wide international variations (Rastogi et al., 2004) (Fig. 1.1). The 
incidence is particularly high in Northeast Asia (Japan, Korea and China), intermediate 
incidences in Eastern Europe, and parts of Central and South America. Incidences are 
low in Southern Asia, North and East Africa, North America, Australia, and New 
Zealand (Brenner et al., 2009; Hartgrink et al., 2009; Parkin et al., 2005). In Singapore, it 
ranks as the 4
th
 most prevalent cancer in males and 6
th
 most common cancer in females 
(Lim et al., 2009). Similar with most other solid tumors, the incidence of GC increases 
with age and the cancer is relatively rare in male or female patients younger than 45 years. 
Most patients are between 60 and 80 years old at diagnosis. In general, incidence and 
mortality rates in men are approximately double to those in women.  
  
Despite the declining incidence globally, the overall five year survival rate of GC is less 
than 24%, which is much lower compared to the other cancers such as breast cancer and 
colorectal cancer (five year survival rates 88.7% and 64.4% respectively) (LAG et al., 
2008). Particularly prevalent in several Asian countries (Kamangar et al., 2006), most GC 
patients present with advanced stage disease with the exception of patients in Japan and 




photofluorography or endoscopy (Hamashima et al., 2008; Lee, 2006). Current strategies 
for treating GC patients are far from optimal, with conventional surgery and 
chemotherapy regimens conferring modest survival benefits and median survival times of 
7-10 months (Jackson et al., 2009) . 
 
1.1.2 Histological subtypes 
 
Gastric carcinomas occur through successive changes. According to Lauren‘s 
Classification, which is the most widely used and accepted approach to classify GC, GC 
is classified into two distinct subtypes: (1) the well differentiated or intestinal type; (2) 
the undifferentiated or diffuse type (Krejs, 2010; Lauren, 1965).  
 
The development of the intestinal type GC includes the transformation of the normal 
mucosa into a mucosa that resembles intestinal epithelium (intestinal metaplasia). The 
presence of intestinal metaplasia increases the risk of GC. Subsequently, intestinal 
metaplasia may progress to dysplasia, and ultimately to carcinoma (Stemmermann, 1994). 
By contrast, diffuse type GC presumably arises as single-cell changes in the mucus neck 
region of the gastric glands. These cells may subsequently proliferate and invade out 
from the crypt (Fig. 1.2). However, some gastric cancers failed to be classified into either 
subtype as they present mixed features of diffuse and intestinal subtypes. These tumors 

















Figure 1.1. Global variations in GC incidence 
The incidence of stomach cancer for men of all ages is highest (orange and red) in 
developing countries such as Asia and South America, and lowest (light and dark green) 
in North America, parts of Africa, India and Australia.  
 







































Figure 1.2.  Histological subtypes of GC 
Upper, gastric carcinoma of intestinal type. Normal mucosa is replaced by infiltrating 
tubular profiles.  
Lower, signet-ring cell gastric carcinoma of the diffuse type. There is diffuse infiltration 
of the mucosa by signet ring cells. The gastric pits appear normal and there is no 
evidence of gastritis or intestinal metaplasia.  
 




1.1.3 Risk factors  
 
Clinical risk factors for GC include Helicobacter pylori (H. pylori) infection, high intake 
of various traditional salt-preserved foods and salt, low consumption of fresh fruits and 
vegetables, smoking and genetic polymorphisms of the host (Hartgrink et al., 2009). 
While familial patterns of GC incidence have been reported, most GC cases are sporadic 
(Barber et al., 2006).  
 
In 1984, Marshall and Warren redetected a gram-negative bacillus, now called H. pylori, 
which is a common inhabitant of the human stomach (Marshall and Warren, 1984). 
Numerous studies conducted since then have consistently found H. pylori infection to be 
related to an increased risk of stomach cancer. In 1994, H. pylori was classified as a 
definite carcinogen for GC (International Agency for Research on Cancer, 1994). 
Infection is usually acquired in childhood. Although the exact mechanisms of action in 
the complex process of stomach cancer are unknown, its action is probably indirect by 
provoking gastritis, a precursor of gastric atrophy, metaplasia, and dysplasia. The 
association between the infection and the subsequent risk of developing GC is about six-
fold (Group, 2001). However, it has been reported that about half of the adult world 
population has been infected but only a small proportion of infected subjects will 
eventually develop GC (Rothenbacher and Brenner, 2003). This indicates that there may 
be other contributing factors involved. 
 
Diet plays an important role. Recently, the World Cancer Research Fund (WCRF) and 
the American Institute for Cancer Research (AICR) did an extensive report on the 




concluded that GC is mostly preventable by appropriate diets and associated factors 
(WCRF and AICR, 2007). Risk is increased by high intake of salt and some traditionally 
preserved salted foods, especially meats and pickles (Palli, 2000). 
 
Additionally, environmental factors have also been recognized as potential factors related 
to the risk of GC. Migrant populations from high-risk countries to low-prevalence 
countries show a significant reduced risk in their second generation. The data fit with 
observations concerning the importance of childhood environment in determining the risk 
(Coggon et al., 1990). 
 
Smoking is another risk factor for GC. The European Prospective Investigation into 
Cancer and Nutrition (EPIC) project found a significant association between cigarette 
smoking and GC risk: the hazard ratio (HR) was 1.45, 1.7 and 1.8 for ever smokers, 
current male and current female smokers respectively. The HR increased with intensity 
and duration of cigarette smoking. In addition, approximately 18% of GC may be 
attributable to tobacco smoking. 
 
Host factors, such as polymorphisms in cytokine genes (eg. Interleukin 1β, interferon γ 
receptor 1) are associated with the increased progression risks of GC (Canedo et al., 2008; 




1.1.4 Prevention and early detection 
 
Patients presenting clinical manifestations of GC have limited options for cure. Thus, 
early detection and prevention play a key role in the fight against GC.  
 
Several studies have gained evidence that the eradication of H. pylori is one of the most 
promising preventive strategies in the fight against GC (Fry et al., 2007; Malfertheiner et 
al., 2005). They have demonstrated that the earlier H. pylori gets eradicated, the lower 
risk of getting GC (Fukase et al., 2008; Wu et al., 2009). However, some other studies 
showed no benefit of H. pylori eradication. One research group reported two cases of GC 
development 4 and 14 years after H. pylori eradication (Cannizzaro and De Paoli, 2009; 
de Vries et al., 2009). These patients presented with gastric ulcer and preneoplastic 
changes (i.e. IM and gastric atrophy) at baseline. Though the role of eradication as the 
main preventive strategy continues to be questioned (De Vries and Kuipers, 2007), the 
effect of eradication and the subsequent risk of developing GC depend on the degree and 
extent of preneoplastic changes (i.e. gastric atrophy and intestinal metaplasia) at the time 
of eradication (Selgrad et al., 2010) .  
 
This suggests that eradication of H. Pylori does not prevent GC in all cases, especially 
those already present with preneoplastic changes. Therefore, it seems that the earlier the 
bacterium gets eradicated, the more significant is the decrease of GC risk. In addition, 
improved knowledge of molecular changes in precursor lesions might enable further 
discrimination between patients at high and low risks. Studies could establish which 




Besides H. pylori eradication, the dominant dietary hypothesis is that fresh fruits and 
vegetables, or contained micronutrients, are protective against GC. Numerous studies 
have shown a protective association with fresh fruits and vegetables, independent of other 
dietary factors (Block et al., 1992; Kono and Hirohata, 1996). Possible protective 
micronutrients include vitamins C (ascorbate) and E (alpha-tocopherol), carotenoids 
(particularly beta carotene), and selenium (Kono and Hirohata, 1996). The evidence is 
strongest for vitamin C, with an approximate halving of risk associated with high intake 
vs. low intake demonstrated in case–control studies (Neugut et al., 1996). 
 
Population-based screening represents one of the best options for the primary prevention 
and early detection of GC especially in the high-risk regions. In Japan, photofluorography 
has been used for GC screening since 1960. About 6 million people are screened annually 
(Miki, 2006).  Serum pepsinogen test, a new and potentially useful method, was 
introduced for mass screening to identify individual with atrophic gastritis who are at 
high risks for GC (Miki, 2006).  To predict the risk of GC development and to diagnose 
atrophic gastritis, serologic testing for a combination of pepsinogen (PG) I and II, and 
gastrin and H. pylori antibodies have yielded accurate results over the last years (Selgrad 





Current strategies for treating GC patients are far from optimal, with conventional 
surgery and chemotherapy regimens conferring modest survival benefits and median 
survival times of 7 to 10 months (Jackson et al., 2009). 
 
Surgical resection of the primary tumor and regional lymph nodes is the treatment of 
choice for GC. However, the extent of disease, the operative procedure, and patient 
selection are crucial in optimizing outcome. Adjuvant therapy (mainly, 
chemotherapy±radiotherapy) still warrants further evaluation for high-risk GC patients. 
Neoadjuvant therapy may reduce tumor mass enabling resection with potentially curative 
intent (Catalano et al., 2009). 
 
Since most GC patients are diagnosed at advanced stages where the tumors are 
unresectable, systemic chemotherapy is the main treatment option. Many single agents 
and combinations are active in the treatment of the metastatic disease. The commonly 
used chemotherapeutic agents include platinum compounds (such as cisplatin), 
fluoropyrimidines, anthracyclines, and, recently, taxanes and irinotecan. The objective 
response rates range from 10% to 30% for single-agent therapy and 30% to 60% for 
combination regimens (Sastre et al., 2006). Although a large number of chemotherapy 
regimens have been tested in randomized studies, there is no internationally accepted 
standard of care, and uncertainty remains regarding the choice of the chemotherapy 





1.1.6 Genetic and genomic alterations in GC 
Like many other cancers, previous cytogenetic studies of GC karyotypes have revealed a 
complex portrait of recurring patterns of chromosomal amplifications and deletions 
associated with GC, including signature genomic gains at chromosomes 7q, 8p, 17q, 20q 
and losses in 5q, 9p, 18q (Kang et al., 2006; Kimura et al., 2004; Nessling et al., 1998; 
Sakakura et al., 1999; Tay et al., 2003). The recurrent nature of these aberrations has been 
attributed to the presence of genes important for gastric carcinogenesis, such as CD44 at 
11p13, CCNE1 at 19q13, and BTAK at 20q13 (Benusiglio et al., 2006; Fukuda et al., 
2000; Husdal et al., 2006; Sen et al., 1997; Tahara, 1995). However, identifying specific 
oncogenes and tumor suppressor genes within such regions is often challenged by their 
large sizes covering tens to hundreds of genes. For example, chromosome 6p 
amplifications have been reported in GC at frequencies ranging from 2-4% using 
conventional comparative genomic hybridization (CGH) platforms to 85% (6p22) by 
cDNA based aCGH (Boussioutas et al., 2003; Gorringe et al., 2005; Nakanishi et al., 
2000; Sakakura et al., 1999), but the specific genes representing the targets of 
amplification in the 6p region are currently unknown.  
 
Studies investigating the genetic basis of GC have also identified germline 
polymorphisms in cytokine genes (e.g. interleukin 1β, TNF-α) (El-Omar et al., 2000; 
Hold et al., 2007). IL-1β and TNF-α are pro-inflammatory cytokines and acid inhibitors 
highly expressed in H. pylori-induced gastritis. Host genetic polymorphisms that affect 





In approximately 30% of familial gastric cancers, a germline mutation in the E-cadherin 
gene (CDH1) is identified (Guilford et al., 1998). CDH1 encodes a transmembrane 
cellular adhesion protein acting as a mediator of homophilic recognition signals, leading 
to cell-cell contact inhibition. The majority of CDH1 mutation carriers were considered 
susceptible to this inherited cancer syndrome dominated by diffuse GC, suggesting a 
central role for this gene as a tumor suppressor in diffuse GC (Guilford et al., 1999).  
 
Somatic mutations in tumor suppressor genes such as p53 and RUNX3 have been 
reported in GC (Li et al., 2002; Pan et al., 2008; Tamura et al., 1991). The tumor protein 
53 gene (p53), the most frequently studied tumor suppressor gene, plays multiple roles in 
carcinogenesis in response to cellular stresses including apoptosis, cell cycle arrest, 
senescence, DNA repair, cell metabolism or autophagy by activating specific target genes 
(Kruse and Gu, 2009).  p53 is the most frequently mutated gene in human cancers. In GC, 
around 45% cases carry the mutated p53 (Soussi et al., 2000).  
 
RUNX3 belongs to the RUNX family of transcriptional factors with conserved Runt-DNA 
binding domain (Chuang and Ito, 2010). Loss of RUNX3 is increasing with tumor grade 
in primary GC samples. Between 45% and 60% of human GC cells do not significantly 
express RUNX3 due to hemizygous deletion and hypermethylation of the RUNX3 
promoter region (Li et al., 2002).  
 
Although knowledge of genomic aberrations and potential oncogenes and tumour-
suppressor genes associated with GC are regarded as a means to reveal new therapeutic 




Therefore, identifying additional molecular aberrations in GC may provide further 
mechanistic insights into GC pathogenesis and highlight opportunities for early detection 
and novel therapies. 




1.2 Fusion gene 
1.2.1 Introduction 
A substantial body of cytogenetic and molecular work over the past has established that 
aneuploidy is a hallmark feature of many cancers, with individual tumors frequently 
exhibiting aberrant patterns of genomic amplifications, deletions, and translocations 
(Albertson et al., 2003; Kallioniemi, 2008). Among the various genomic aberrations, 
fusion genes make an important contribution to the development of cancer due to their 
cancer-specific nature (Heim and Mitelman, 2008).  
 
Fusion genes are hybrid genes formed by the combination of two previously separate 
genes (Fig.1.3). In cancers, fusion genes can be produced by genomic amplifications, 
deletions, translocations and rearrangements (Mitelman et al., 2007). The prevailing view 
is that such fusion transcripts and proteins are abnormal thereby providing tumor cells 
with growth and survival advantages. Most importantly, they may serve as specific 
diagnostic markers and therapeutic targets due to their cancer specific nature.   
 
The first specific translocation identified by Nowell and Hungerford in 1961 in human 
neoplasia was t(9;22)(q34;q11), resulting in the Philadelphia chromosome (Nowell and 
Hungerford, 1960) (Fig.1.4). The fusion gene brings together the 5‘ part of BCR gene at 
22q11 and the 3‘ part of the ABL1 tyrosine kinase-encoding gene at 9q34, leading to a 
hybrid BCR-ABL1 protein with increased tyrosine kinase activity (Look, 1997; Rabbitts, 
1994), which is essential for the initiation, maintenance and progression of Chronic 
Myelogenous Leukemia (CML) (Ren, 2005). BCR–ABL1 is a diagnostic marker for CML. 




diagnosis, and to monitor cytogenetic remission and residual disease (Ren, 2005). Most 
importantly, BCR–ABL1 is a specific therapeutic target. Imatinib (or Gleevec), a small-
molecule inhibitor of ABL1 tyrosine kinase activity, is used as the standard treatment for 
chronic-phase CML (Druker et al., 2006; Hughes et al., 2003; O'Brien et al., 2003). 
Subsequently, the identification of the t(8;14)(q24;32) in Burkitt‘s lymphoma, which 
juxtaposes MYC with the immunoglobulin heavy chain gene, dramatically increased our 
understanding of the pathogenetic significance of translocations and gene fusions in the 
origin of human cancers (Rabbitts and Boehm, 1991). Since then, an increasing number 
of gene fusions have been recognized as important diagnostic and prognostic markers in 
malignant haematological disorders and sarcomas. The biological and clinical impact of 
gene fusions in the more common solid tumor types are less appreciated. Until recently, 
with the advent of new and powerful investigative tools, fusion genes have been 
identified in solid tumors, suggesting that causal gene rearrangements exist in common 
epithelial cancers. 
 
1.2.2 Types of gene fusions 
There are generally two types of gene fusions. In the first, the promoter or the enhancer 
element of one gene is juxtaposed to an oncogenic gene, leading to an up-regulation of 
the second gene (eg IgH-Myc) (Fig.1.5) (Rabbitts and Boehm, 1991). As a consequence 
of the translocations, the MYC gene becomes constitutively expressed owing to the 
influence of regulatory elements of the immunoglobulin genes. An analogous scenario is 
seen in T-cell lymphomas and T-cell acute lymphoblastic leukemia (ALL) in which 







Figure 1.3. Fusion RNAs  
Chromosomal translocation can give rise to fusion mRNAs. Some chromosomal 
translocations produce two hybrid genes that may produce mRNAs containing the 5‘ end 
of one gene and the 3‘ end of the other.  
 














Figure 1.4. Philadelphia chromosome  
The BCR-ABL fusion protein results from reciprocal translocation of the BCR gene from 
chromosome 22 with the ABL gene from chromosome 9. 
 




partner genes (Aplan, 2006; Mitelman et al., 2007). Immunoglobulin and T-cell receptor 
genes are frequently involved in chromosomal aberrations because they are naturally 
rearranged to generate active antigen-receptor genes. This process occasionally, in error, 
leads to an interchromosomal translocation or inversion. In addition, deregulation as a 
consequence of promoter swapping or substitution has also been identified in some 
benign and malignant solid tumors (eg. TMPRSS2-ETS in prostate cancer) (Tomlins et al., 
2005).  
 
In the second type, gene fusions lead to a production of chimeric protein with oncogenic 
signaling potential (eg BCR-ABL) (Fig.1.6) (de Klein et al., 1982). The fusion of BCR 
sequences to ABL generates a new protein with increased tyrosine kinase activity of ABL, 
and brings new regulatory domains/motifs to ABL. Many hybrid genes, accounting for 
approximately 75% of the known gene fusions in malignant disorders, have been 
identified in various haematological malignancies and solid tumors (Mitelman et al., 
2007).  
 
To date, most of reported fusion events involve two main groups — transcription factors 
and tyrosine kinases. They account for 50% of the genes involved and distributed quite 























Figure 1.5. Gene fusion leading to gene upregulation (Type 1)  
The t(8;14)(q24;q32) translocation, the most common translocation in Burkitt lymphoma, 
leads to the deregulation of the MYC gene at 8q24 through its juxtaposition with 
regulatory elements of the immunoglobulin heavy chain (IGH) gene at 14q32; that is, the 















Figure 1.6. Gene fusion leading to a chimeric gene (Type 2)  
The Philadelphia chromosome, which originates through the translocation 
(9;22)(q34;q11), juxtaposes the 5′ part of the BCR gene at 22q11 with the 3′ part of the 
ABL1 gene at 9q34, resulting in the creation of a hybrid BCR–ABL1 fusion gene. 
 




 1.2.3 Balanced and unbalanced rearrangements 
 
Gene fusions can arise from either balanced or unbalanced rearrangements. Balanced 
rearrangements refer to chromosome abnormalities that give rise to structurally altered 
chromosomes without the gain or loss of genetic material. Such changes comprise of 
reciprocal translocations and inversions. On the other hand, unbalanced rearrangements 
refer to chromosomal abnormalities involving gain or loss of genetic material, such as 
duplications, amplification insertions or deletions.  
 
To date, more than 300 fusion genes have been identified in human malignancies, the 
majority of which are the result of balanced chromosomal rearrangements (Mitelman et 
al., 2007). Examples of fusions resulting from balanced translocations are IGH–MYC in 
Burkitt lymphoma/leukaemia rabbitts (Rabbitts and Boehm, 1991); BCR–ABL1 in CML 
(de Klein et al., 1982); PML–RARA in acute promyelocytic leukaemia (Ghaffari et al., 
2006); JAZF1–SUZ12 in endometrial stromal sarcoma.  
 
Examples of gene fusions that are typically detected in the context of an unbalanced 
cytogenetic rearrangement include COL1A1–PDGFB in dermatofibrosarcoma 
protuberans with supernumerary ring chromosomes (Sirvent et al., 2003); NUP214–ABL1 
(Graux et al., 2004) occurring on amplified episomes in T-cell ALL; TMPRSS2–ERG in 
prostate cancer (Tomlins et al., 2005). The majority of translocations described in human 
cancer are unbalanced (Mitelman et al., 2004). The analysis of unbalanced translocations 
has largely failed to identify target genes because of the heterogeneity of the 
chromosomal breakpoints and the multiplicity of partner chromosomes. Thus, it has been 




chromosomal material. Identification of the key molecular events resulting from 
unbalanced rearrangements would be a significant step toward understanding their role in 
cancer pathogenesis (An et al., 2008). 
 
1.2.4 Fusion genes in hematological malignancies 
To date, more than 80% of gene fusions have been identified in haematological disorders, 
including malignant lymphomas and most of them were identified through standard 
cytogenetic assays such as spectral karyotyping (SKY) or fluorescence in situ (FISH) 
Hybridization (Maher et al., 2009; Mitelman et al., 2007). Fusion events have been well 
documented and recognized as causal events to some heamatological malignancies. They 
have been used to identify particular cancer subtypes (eg PML-RAR in acute 
promyelocytic leukemia) and specifically targeted using drugs (eg BCR-ABL in CML) 
(Deininger et al., 2005; Ghaffari et al., 2006). 
 
The acute promyelocytic leukemia (APL)-specific t(15;17) chromosome abnormality is 
characterized at the molecular level by rearrangement of the PML and RAR alpha genes, 
resulting in fusion PML/RAR alpha mRNA and a chimeric protein. Besides its relevance 
in the pathogenesis of the disease, this hybrid gene represents a specific tumor marker. 
Several studies have highlighted the clinical relevance of PML/RAR alpha detection to 
identify APL. In fact, this hybrid gene can be detected in 100% of APLs (Ghaffari et al., 
2006). 
 
In CML, the most frequent chromosomal translocation is t(9;22) which causes fusion of 




constitutive tyrosine kinase activity and complex interactions of this fusion protein with 
many other transforming elements, such as the signaling pathway for RAS (GTP-binding 
protein that activates target genes involved in cell differentiation, proliferation, and 
survival) (Ren, 2005). As an activated kinase, BCR-ABL offers an attractive therapeutic 
target, and imatinib, a small-molecule inhibitor of the ABL kinase, has proven effective 
against leukaemias that express BCR-ABL (Druker, 2004; Pui et al., 2008). 
 
About 25% of cases of B-cell precursor ALL, which is the most frequent form of acute 
leukaemia in children, harbor the TEL-AML1 fusion gene generated by the 
t(12;21)(p13;q22) chromosomal translocation (Pui et al., 2004). Although the molecular 
pathogenesis of TEL-AML1 positive leukaemia remains unclear, findings in mice 
establish the TEL gene as an important regulator of haemopoietic-cell development, 
essential for definitive hematopoiesis (Hock et al., 2004). Similarly, AML1 gene is 
essential for definitive embryonic hematopoiesis (Okuda et al., 1996; Wang et al., 1996). 
Thus, the presence of the TEL-AML1 fusion protein in B-cell progenitors may lead to 
disordered early B-lineage lymphocyte development, a hallmark of leukaemic 
lymphoblasts (Pui et al., 2008). 
 
1.2.5 Fusion genes in solid tumor 
In contrast to hematologic malignancies where the existence and importance of fusion 
genes are well-documented, our knowledge of fusion genes is lacking in solid epithelial 
tumors. In solid tumor, efforts at fusion gene discovery are traditionally hampered by 
many challenges, ranging from technical difficulties (sample handling, preparation of 




in individual tumors that may confound standard cytogenetic assays (Heim and Mitelman, 
2008).  
 
Intriguingly, more than 80% of all known gene fusions are attributed to leukemias, 
lymphomas and bone and soft tissue sarcomas which account for only 10% of all human 
cancers. In contrast, common epithelial cancers, which account for 80% of cancer-related 
deaths, only attributed to 10% of known recurrent gene fusions (Kumar-Sinha et al., 2008; 
Mitelman et al., 2005). Gene fusions described among epithelial cancers have included 
RET–NTRK1 fusions in papillary thyroid carcinoma, PAX8–PPARG in follicular thyroid 
carcinoma, MECT1-MAML2 in mucoepidermoid carcinoma, TFE3–TFEB in kidney 
carcinomas, and BRD4–NUT in midline carcinomas (Kumar-Sinha et al., 2008). 
Remarkably, recurrent gene fusions have not been detected in the most prevalent 
carcinomas, such as prostate, breast, lung, and gastrointestinal tumours (Mitelman, 2000). 
 
However, recently, one research group in Michigan University reported a recurrent fusion 
transcript TMPRSS2-ERG in prostate tumor and subsequently Soda et al. identified a 
fusion transcript EML4-ALK in non-small-cell lung cancer (Fig.1.7 and Fig.1.8) (Soda et 
al., 2007; Tomlins et al., 2005). The prevalence of gene fusions in these two types of 
cancers are ~ 50% and 5% respectively, suggesting that the prevalence of solid cancer 
subtypes characterized by recurrent gene fusions varies across different cancer types. 
Nevertheless, these studies established that oncogenic gene rearrangements do exist in 






In 2010, we used transcriptome sequencing to identify BRAF-related gene fusions in GC, 
providing pioneering evidence for this important class of molecular aberrations in 






























Figure 1.7. Identification of TMPRSS2:ETV1 and TMPRSS2:ERG gene fusions in 
prostate cancer (PCA) 
Schematic of TMPRSS2 with ETV1 fusion in MET26-LN and ERG fusion in MET28-LN. 
 









Figure 1.8. Gene fusion between EML4 and ALK in Non-small-cell lung cancer 
Both the ALK gene and the EML4 gene map to chromosome 2p, but have opposite 
orientations.  
 




1.2.6 Fusion gene identification using genomic breakpoint analysis (GBA) 
Identification of fusion genes has evolved with improvements in technology. One 
approach is genomic breakpoint analysis (GBA) using array based technology that allows 
the identifications of amplifications, deletions and allelic imbalances (Nannya et al., 2005; 
Tsukamoto et al., 2008). GBA identifies putative chromosomal breakpoints by examining 
closely spaced microarray probes displaying prominent transitions in copy number status, 
from low to high copy number or vice versa. We have discussed previously that gene 
fusions can arise from balanced or unbalanced chromosome rearrangements. However, 
genomic breakpoint analysis using high resolution array based technology only detects 
changes of gene dosage and is unable to identify balanced translocations (Fig.1.9). 
 
Using genomic breakpoint analysis, one research group has recently identified novel 
PAX5 fusion transcripts in leukemia using high-resolution SNP arrays, reiterating the 
ability of a high resolution genomic approach in identifying fusion genes (Fig.1.10) 
(Kawamata et al., 2008). Although such studies have demonstrated that GBA can 
discover novel fusion genes in leukemia, it is currently unclear if GBA can also be 
successfully applied to solid epithelial cancers, due to increased genomic complexity in 































Figure 1.9. Copy number analysis detected genes involved in unbalanced 
translocations 
Copy number analysis can identify breakpoints of translocations when one of the paired 
translocated chromosomes is either lost or duplicated/amplified. (Left) Chromosomal 
status. Gene dosages are indicated either above or beneath the chromosomes. (Right) 
Results of SNP-chip analysis. 
i,   normal chromosomes; gene dosage is normal.  
ii, reciprocal translocation; gene dosage is normal.  
iii, one of the paired translocated chromosomes is lost; gene dosage is lower than normal 
on the left side of the upper chromosome and the right side of the lower chromosome. 
Arrow heads indicate the breakpoint of the translocation in each chromosome. 
iv, one of the paired translocated chromosomes is duplicated; gene dosage is higher than 
normal on the right side of the upper chromosome and the left side of the lower 
chromosome. Arrow heads indicate the breakpoint of this translocation in each 
chromosome. 
 








Figure 1.10.  PAX5 gene is fused to partner genes 
Left, start sites of deletion at 9p13.2 involving the PAX5 gene. (Left) SNP-chip data of 
representative cases with 9p13.2 deletions. A vertical arrow indicates the start sites of 9p 
deletion that involves the PAX5 gene. A horizontal arrow shows the direction of 
transcription of the PAX5 gene. (Right) Chromosomal abnormalities of partner 
chromosomes. Arrow heads indicate the start sites of duplication or deletions. Genes 
involved in the start sites are shown. 
Right, Fusion sequences of the PAX5 and partner genes. Joining sequences of fused 
transcripts are shown from the indicated exon of the fused gene. 
 






1.3.1 CD44 family 
CD44 is a transmembrane glycoprotein that acts as a hyaluronan-binding surface receptor. 
It is a major adhesion molecule for the extracellular matrix (ECM) and has been 
implicated in a wide variety of physiological processes (Ponta et al., 2003). Numerous 
isoforms of CD44 exist through alternative mRNA splicing (Fig.1.11). They are encoded 
by a single, highly conserved gene located on chromosome 11, which contains 20 exons. 
10 of which can be differentially spliced.  All isoforms have 5 constant exons at the 
amino terminus followed by 10 alternatively spliced exons, 2 constant membrane-
proximal coding exons, 1 constant transmembrane-coding exon, and 2 potentially 
alternatively spliced exons coding for cytoplasmic domains (Schmits et al., 1997). The 
great variability in splicing leads to at least 18 different CD44 isoforms (Screaton et al., 
1993; Tolg et al., 1993). The smallest CD44 isoform, which is known as CD44 standard 
(CD44s), is predominantly expressed in hematopoietic cells and normal epithelial cell 
subsets, whereas the larger variant isoforms (CD44v) with the membrane-proximal 
extracellular region are abundant in some epithelial-type carcinomas (Ponta et al., 2003; 
Tanabe et al., 1993).  
 
1.3.2 Molecular function of CD44 
CD44 may provide a link between the plasma membrane and the actin cytoskeleton. 
CD44 is among a group of proteins that crosslink transmembrane receptors to the actin 































Figure 1.11. CD44 transcripts 
CD44 pre-mRNA is encoded by 20 exons, 10 of which can be regulated by alternative 
splicing (variant or ‗v‘ exons). The smallest CD44 isoform, which is known as CD44 
standard (CD44s), is ubiquitously expressed in vertebrates in developing and adult 
organisms, whreas the larger variant isoforms are expressed in some epithelial tissues and 
in several cancers.  
 







CD44 might establish the dynamics that are required for cellular movement (Tsukita et al., 
1994). 
 
CD44 has co-receptor functions that mediate the signaling of receptor tyrosine kinases. 
This function of CD44 proteins is important for at least a small group of receptor tyrosine 
kinases, which includes Met and members of the ERBB family of receptor tyrosine 
kinases (RTK) (Orian-Rousseau et al., 2002). 
 
CD44 binds ligands, which influences cellular behaviors independent of interactions with 
receptor tyrosine kinases or the actin cytoskeleton, these functions include its adhesion to 
hyaluronan and other components of ECM, as well as axon deterrence, its action as a 
platform for growth factors and other molecules, and its regulation of assembly, 
disassembly or uptake of pericellular hyaluronan-based matrices (Stamenkovic et al., 
1991). 
 
1.3.3 CD44 function in health and disease 
CD44 is expressed in most human cell types and is implicated in a wide variety of 
physiological processes, including lymphocyte homing and activation, regulation of 
growth, survival, differentiation and motility (Nagano and Saya, 2004; Ponta et al., 2003). 
CD44 proteins have essential functions in life and altered expression or dysfunction 
causes pathogenic phenotypes. 
 
In 1991, it was reported that an alternative spliced form of CD44 could confer metastatic 
capacity to a rat pancreatic carcinoma cell line. Since then, a vast number of publications 




metastasis and their relevance as diagnostic and prognostic parameters for human tumors, 
such as breast, colorectal and lymphomas (Combaret et al., 1996; Herrlich et al., 1993; 
Imazeki et al., 1996; Stauder et al., 1995).  However, there are some tumor types 
including neuroblastomas and prostate carcinomas, in which the absence of CD44 variant 
expression correlates with transformation and poor prognosis, and overexpression of 
CD44 in prostate carcinoma cells even suppressed metastatic behavior (De Marzo et al., 
1998; Gao et al., 1997; Shtivelman and Bishop, 1991). Although studies showed 
controversial results on CD44 function in cancers, substantial evidence suggested that 
aberrant expression of CD44 and CD44 variants are associated with many human tumors. 
 
In addition, CD44 has recently been identified as one of the cell surface markers 
associated with cancer stem cells (CSCs) in several types of tumors (Al-Hajj et al., 2003; 
Collins et al., 2005; Dalerba et al., 2007). CSCs are malignant cell subsets in 
hierarchically organized tumors; they are selectively capable of tumor initiation and self-
renewal and give rise to the bulk population of nontumorigenic cancer cells through 
differentiation. However, the underlying mechanisms for the emergence of CD44 positive 
CSCs during tumorigenesis have not been elucidated (Ishimoto et al., 2011). 
 
1.3.4 CD44 and GC 
Comparative genomic hybridization (CGH) study has detected frequent 11p13 
amplifications in GC (Fukuda et al., 2000). The minimal common region at 11p13, within 
the 11p11.2–14 amplicon, harbors the CD44 gene. In addition, expression of CD44v has 
been previously shown to be associated with progression of human gastrointestinal 




expressed in mouse gastric tumors, being highly abundant in proliferative cells and slow-
cycling stem-like cells (Ishimoto et al., 2010). CD44v may function to interact with a 
glutamate-cystine transporter, and control the intracellular level of reduced glutathione 
(GSH) in human gastrointestinal cancer cells. High levels of CD44 expression showed an 
enhanced capacity for GSH synthesis and defense against reactive oxygen species (ROS). 
Ablation of CD44 resulted in suppressed tumor growth in a transgenic mouse model of 
GC. These findings establish a function for CD44v in regulation of ROS defense and 








1.4 Excitatory amino acid transporters (EAATs)  
1.4.1 Glutamate and EAATs 
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous 
system (CNS). It is estimated that ~ 40% of all neurons distributed throughout the CNS 
involve this amino acid (Bunch et al., 2009). Glutamate plays a central role in normal 
brain functions including cognition, memory, and learning (Riedel et al., 2003). However, 
excessive elevation of the extracellular glutamate concentration mediates excitotoxicity 
and causes neuronal cell death (Beal, 1992). Glutamate has been implicated in many 
pathological conditions such as epilepsy, cerebral ischemia, myotrophic lateral sclerosis, 
Alzheimer‘s disease, Parkinson‘s disease and schizophrenia (Amara and Fontana, 2002; 
Danbolt, 2001). There is no enzymatic system available for metabolizing glutamate in the 
extracellular space; the only way to maintain glutamate homeostasis is through glutamate 
uptake via glutamate transporters (Danbolt, 2001; Wu et al., 2010). 
 
Excitatory amino acid transporters (EAATs) are high-affinity, sodium-dependent 
glutamate carriers from solute carrier family 1 (SLC1) in the CNS, which maintain 
extracellular glutamate concentrations and contribute to the clearance of glutamate 
released during neurotransmission (Gebhardt et al., 2010). At least five sodium-
dependent glutamate transporter subtypes have been identified and characterized: EAAT1 
(SLC1A3) (Storck et al., 1992), EAAT2 (SLC1A2) (Pines et al., 1992), EAAT3 
(SLC1A1) (Kanai and Hediger, 1992), EAAT4 (SLC1A6) (Fairman et al., 1995), and 
EAAT5 (SLC1A7) (Arriza et al., 1997). EAAT3 and EAAT4 are localized predominantly 
in neurons, and EAAT5 is enriched in retinal tissue, whereas EAAT1 and EAAT2 are 




excitatory synaptic contacts (Sims and Robinson, 1999). Among the five known human 
EAAT subtypes, EAAT1 and EAAT2 have the greatest impact on clearance of glutamate 
released during neurotransmission. Studies of EAAT3, EAAT4 and EAAT5 suggest more 




EAAT2 (Hereafter refer as SLC1A2) gene has been mapped to chromosome 11p13(Li and 
Francke, 1995), showing a genomic structure of 11 protein coding exons, spanning more 
than 55 kb genomic DNA (Meyer et al., 1997).  Several homologous transcript variants 
of SLC1A2 have been identified, showing a heterogeneity of the 5‘ untranslated sequence 
and a variability of the N-terminal amino acids of the putative proteins (Arriza et al., 
1994; Meyer et al., 1998; Munch et al., 1998). The SLC1A2 cDNA contains an open 
reading frame of 1722 bp encoding for a predicted protein of 574 amino acids (Meyer et 
al., 1998). 
 
SLC1A2 is responsible for more than 90% of glutamate uptake in the brain (Boudker et 
al., 2007; Gebhardt et al., 2010).  It is predominantly expressed in astrocytes and 
functions to transport glutamate into astrocytes for conversion into glutamine, which is 
then released and recycled by neurons to generate glutamate. This process is thought to 
contribute to energy metabolism in the brain, because if glutamate was not recycled by 
conversion into glutamine and had to be synthesized repeatedly, glucose consumption in 
the brain would be much higher (Lauriat and McInnes, 2007; Marcaggi and Attwell, 




neurological disorders such as ischemia, Alzheimer‘s disease and Huntington‘s disease 
(Su et al., 2003; Ye et al., 2010). These findings emphasize the importance of glutamate 
transport and the SLC1A2 transporter in astrocytes to normal brain function and their 
association with multiple pathologic changes in the brain (Su et al., 2003).  
 
1.4.3 Glutamate and cancer metabolism 
The Warburg effect, describes the propensity for cancer cells and tissues to take up 
glucose avidly and convert it almost exclusively to lactate (aerobic glycolysis). This 
effect has been proposed to have a central role in cancer cell metabolism (Kroemer and 
Pouyssegur, 2008; Vander Heiden et al., 2009). Although the glycolytic pathway 
generates ATP and produces metabolic intermediates for cancer cells, glucose can only 
provide carbon source. Glutamine is another essential nutrient for cancer cells and is an 
abundant amino acid in the serum. Essential functions of glutamine include its conversion 
to glutamate as a metabolic intermediate to be channeled into the tricarboxylic acid (TCA) 
cycle and its function as a precursor for the biosynthesis of nucleic acids, certain amino 
acids, and glutathione (Lu et al., 2010) (Fig. 1.12). 
 
There is an expanding body of literature suggesting that glutamate is likely to behave as a 
critical amino acid metabolite in many cancers (Rzeski et al., 2001; Takano et al., 2001). 
Glutamate levels have been shown to be elevated in many cancers including GC, and 
glutamate deprivation has been shown to sensitize cancer cells to apoptotic stimuli 
(Okada et al., 1993; Rothstein et al., 1996). The exact mechanistic requirement of cancer 
cells for glutamate is an active area of study, and may be related to the Warburg effect. It 




in their ability to shuttle glycolytic metabolites into the Kreb's cycle to generate ATP. 
Because glutamate (and its sister amino acid glutamine) can be converted intracellularly 
into alpha-ketoglutarate, the availability of glutamate could thus provide a secondary 











Figure 1.12. Glutamine metabolism 
The interconnection between glutamine metabolism and glucose metabolism is also 
shown. GLS, glutaminase; TCA cycle, tricarboxylic acid cycle; MRC, mitochondrial 
respiratory chain; V, mitochondrial respiratory complex V; OAA, oxaloacetate; Asp, 
aspartate; a-KG, a-ketoglutarate. 
 




1.5 Rationale of the study 
Fusion genes are of exceptional interest to the cancer biology community due to their 
cancer specific nature (being produced by genomic aberration events). They represent 
ideal drug targets and diagnostic markers (Mitelman et al., 2007). In blood cancers, 
fusion genes are routinely used to diagnose particular clinical subtypes, and treatment of 
CML, once a uniformly lethal cancer, has been revolutionized by gleevec, which targets 
the BCR-ABL fusion gene (Druker et al., 2006; Hughes et al., 2003; O'Brien et al., 2003). 
In contrast to the blood cancers, few recurrent fusion genes have been identified in solid 
epithelial cancers (eg gastric, colon, lung and breast) to date. However, recent studies 
such as TMPPRS2-ERG (prostate cancer) and EML4-ALK (non-small-cell lung cancer) 
have shown that fusion genes do exist in solid tumors, and that these entities may be 
uncovered using high-resolution genomic approaches (Soda et al., 2007; Tomlins et al., 
2005). Thus, we intend to apply high resolution genomic approaches to identify possible 
fusion transcripts in GC, the second highest cause of global cancer mortality (Hartgrink et 
al., 2009). 
 
The specific aims for the current study are listed below:  
 
1. Identify genes located at the breakpoints of chromosomal aberrations in human 
gastric cancer cell lines (GCCLs) and gastric tumors using GBA 
2. Identify possible fusion transcripts using cell line models 
3. Perform functional studies on recurrent fusion transcripts in vitro and in vivo 
4. Examine recurrence of the fusion in primary gastric tumors  




Chapter II: Material and Methods 
 
 
2.1 Primary tissues and cell lines 
Primary gastric tumors and normal tissues were obtained from the Singhealth Tissue 
Repository, an institutional resource of National Cancer Centre of Singapore and 
Singapore General Hospital. All patient samples were obtained with informed patient 
consent and approvals from Institutional Review Boards and Ethics Committees. Gastric 
cancer cell lines (GCCLs) AGS, KATO III, SNU1, SNU16, N87, and Hs746T were 
purchased from the American Type Culture Collection (ATCC). AZ521, Ist1, TMK1, 
MKN1, MKN7, MKN28, MKN45, MKN74, Fu97, and IM95 cells were obtained from 
the Japan Health Science Research Resource Bank. SCH cells were provided by Yoshiaki 
Ito (Cancer Sciences Institute of Singapore). YCC cells were a gift from Sun-Young Rha 
(Yonsei Cancer Center, South Korea). HFE145 cells were a gift from Hassan Ashktorab 




2.2 Cell culture  
 
2.2.1 Culture of gastric cancer and normal cell lines  
 
SNU16 cells were maintained in RPMI 1640 (National Cancer Center Medium Prep, 
Singapore) containing 10% heat-inactivated Fetal Bovine Serum (FBS) (Gibco, 
Invitrogen Singapore), 1% Penicillin-Streptomycin (Gibco, Invitrogen Singapore), 0.1 
mM Non-Essential Amino Acids Solution (Gibco, Invitrogen Singapore) and 2 mM L-
glutamine (Gibco, Invitrogen Singapore). Cells were cultured in 75 cm
2
 tissue culture 
flasks (Corning Life Sciences, USA) in 37
o
C incubator with 5% carbon dioxide in a 
water saturated environment. Cell morphology was monitored every day to ensure that 
healthy cells were used for the experiments. When cells reach 90% confluency for 
subculture, cells were collected and centrifuged for 3 min at 1,500 rpm. Then supernatant 
was removed and the cell pellet was washed with warm sterile Phosphate-Buffered saline 
(PBS) (National Cancer Center Medium Prep, Singapore) and centrifuged for 3 min at 
1,500 rpm. After removing supernatant, cell pellet was resuspended in medium and 
divided into new tissue culture wares with a ratio of 1:4. 
 
AGS cells were maintained in the same medium and condition as SNU16 cells mentioned 
above. Cell morphology was monitored every day to ensure that healthy cells were used 
for the experiments. When cells reach 90% confluency for subculture, the medium was 
discarded and the adherent cell monolayer was gently washed with PBS. Appropriate 
amounts of 0.25% trypsin-EDTA (National Cancer Center Medium Prep, Singapore) was 




supernatant was removed and the cell pellet was resuspended in medium and divided into 
new tissue culture wares with a ratio of 1:4. 
 
HFE145 cells were cultured in Dulbecco‘s Modified Eagle Medium (DMEM) (National 
Cancer Center Medium Prep, Singapore) containing 10% heat-inactivated FBS, 1% 
Penicillin-Streptomycin, 0.1 mM Non-Essential Amino Acids Solution and 2 mM L-
glutamine. Cells were maintained in T75 tissue culture flasks in 37
o
C humidified 
incubator with 5% carbon dioxide through subcultures as a ratio of 1:4. Subculturing of 
cells was performed as AGS cells described above.  
 
2.2.2 Quantification of cell number 
Cell viability was determined by mixing 10 µl of diluted cell suspension with 10 µl of 
Trypan blue solution (Sigma Aldrich, USA). Approximately 10 µl of the cell mixture was 
loaded into C-Chip disposable hemocytometer (Digital Bio Technology, UK). Viable 
cells were counted under CKX41 microscope (Olympus, USA) and corresponding cell 
number was calculated accordingly.  
 
Alternatively, 10 µl of the cell mixture (cell suspension and trypan blue solution) was 
loaded into the Invitrogen Countess
TM
 counting chamber (Invitrogen, Singapore). The 
chamber was then analysed in the Invitrogen Countess
TM
 automated cell counter 
(Invitrogen, Singapore). The value indicating cell concentration of the mixture was 
shown and multiple 2X of the value to determine the actual concentration of the original 





2.3 DNA isolation 
DNAs were isolated from primary gastric tumor and normal tissues and gastric cancer 
cell lines using Qiagen Blood and Cell Culture DNA extraction kit (QIAGEN, Germany). 
DNA yields were determined using Nanodrop 2000 (Thermo Scientific Inc. USA) and 
DNA quality was determined using a 0.5% agarose gel. 
 
2.3.1 DNA extraction from primary gastric tissues 
Primary tissue samples were cut and weighed accordingly. Tissues were grind to fine 
powder with liquid nitrogen in a pre-cooled mortar and pestle. Tissues were homogenized 
with 2 ml Buffer G2 (with 4 µl RNase A). 0.1 ml proteinase K stock solution were added 
to the homogenate and mixed by vortexing. Samples were incubated at 50°C overnight.  
 
After incubation, the samples were used for genomic DNA extraction using Genomic-tip 
Protocol following manufacturer‘s instruction. Briefly, QIAGEN Genomic-tip 20/G was 
equilibrated with 1 ml Buffer QBT. After equilibration, samples were applied to the 
genomic-tip and entered the resin by gravity flow. Next, genomic-tip was washed with 1 
ml Buffer QC for three times. The genomic DNAs were eluted with 2 x 1 ml of Buffer 
QF. 1.4 ml isopropanol was added to the eluted DNA to precipitate the DNA. Samples 
were mixed and centrifuged immediately at >5000 g for at least 15 min at 4°C. 
Supernatant was carefully removed. Subsequently, DNA pellets were washed with 1 ml, 
cold 70% ethanol and centrifuged again at >5000 g for 10 min at 4°C. Supernatants were 
removed without disturbing the pellets. Pellets were air-dried for 5–10 min and 





2.3.2 DNA extraction from cultured cells 
Frozen cell pellets were washed with PBS and resuspended in 0.5 ml PBS. 0.5 ml ice 
cold buffer C1 and 1.5 ml of distilled water were added to the cell suspension. The 
samples were mixed by inverting the tube several times and incubated for 10 min on ice. 
After incubation, lysed cells were centrifuged at 4°C for 15 min at 1300 g. Supernatants 
were discarded. Subsequently, 0.25 ml ice-cold Buffer C1 and 0.75 ml ice-cold distilled 
water were added to the pellets. The pelleted nuclei were resuspended by vortexing and 
centrifuged again at 4°C for 15 min at 1300 g. 1 ml Buffer G2 was added to the pellets 
and completely resuspended by vortexing for 10–30 sec at maximum speed. After 
vortexing, 25 µl Proteinase K stock solution was added and the samples were incubated 
at 50°C water bath for 30–60 min. 
 
After incubation, the samples were used for genomic DNA extraction using Genomic-tip 




 2.4 Agilent 244k aCGH profiling and Genomic Breakpoint Analysis (GBA) 
106 primary tumors and 27 cell lines were profiled using Agilent 244K Human Genome 
Microarrays (Agilent Technologies, Santa Clara, CA), which contained In situ 
synthesized 60 mer oligo probes covering both the coding and non-coding sequences of 
total genomic DNA with an average spatial resolution of approximately 6 kb. Briefly, 
Genomic DNA isolated from samples and control genomic DNAs (human spleen DNA) 
were labeled with Cy3-dUTP and Cy5-dUTP (Agilent Genomic DNA Labeling Kit 
PLUS) respectively (Agilent Technologies, Santa Clara, CA). Subsequently, entire 
reaction product was hybridized onto the microarray using the Agilent aCGH 
Hybridization Kit (Agilent Technologies, Santa Clara, CA). Microarrays were washed 
using the Agilent aCGH Wash Kit (Agilent Technologies, Santa Clara, CA). For each 
DNA probe on the microarray, the ratio of intensity of the fluorescence measured for the 
two fluors was determined by scanning through Agilent DNA Microarray Scanner 
(Agilent Technologies, Santa Clara, CA). A red color represents increased DNA copy 
number, green represents decreased copy number (i.e., deletion), and yellow represents 
no change in DNA copy number in tumor cell DNA compared with normal cell DNA. 
Data were extracted using Agilent‘s Feature Extraction version 9.1 software and analyzed 
using Agilent‘s CGH Analytics version 3.5 software (Agilent Technologies, Santa Clara, 
CA). Genomic breakpoint analysis was then carried out using a Z-score algorithm with a 





2.5 Fluorescence in-situ Hybridization (FISH) 
SNU16 interphase and metaphase cell pellets were prepared for FISH analysis by 
standard hypotonic treatment and fixation after colcemide exposure (10 µg/ml) for 2 hrs. 
Prior to hybridization, cells were pre-treated with pepsin (100 mg/ml) (Sigma, USA) and 
0.01 mol/L HCl at 37°C (5 min), fixed in 1% formaldehyde (Sigma, USA) (10 min), and 
dehydrated in an ethanol series. Fosmid and BAC probes were obtained from BACPAC 
Resource Center (BPRC, CHORI, Oakland, California, USA), and grown following 
vendor instructions. DNA was extracted with Nucleobond PC500 (Macherey-Nagel), 
followed by labeling with either biotin-16-dUTP (Roche, Germany) or digoxigenin-11-
dUTP (Roche, Germany) using an Enzo Nick Translation DNA labeling system. 
Approximately 20 ng of each probe was used per hybridization in addition to 10 ug of 
Cot1-DNA (Invitrogen, USA). The slides and probes mixes were codenatured on a hot 
plate set at 75°C and hybridized overnight at 37°C. Post hybridization washes were 
performed at 45°C in pre-warmed formamide 50%/2X SSC solution (twice), followed by 
two washes in 2X SSC (twice). Slides were blocked with blocking reagent (Roche, 
Germany), followed by incubation with avidin-conjugated fluorescein isothiocyanate 
(FITC) (Roche, Germany) and anti-Digoxygenin-Rhodamine (Roche, Germany) 
respectively. DAPI counterstain (Vector Laboratories, USA) was then used to stain the 
nuclei to enable visualization. Slides were mounted with vectashield (Vector Laboratories, 
USA). Fluorescence images were captured with a 60X objective using a cooled charge-
coupled device (CCD) camera attached to a Nikon fluorescence microcscope.  Automated 





2.6 RNA isolation 
Total RNA were extracted from primary gastric tissues and gastric cancer cell lines using 
Qiagen RNeasy® mini kit (QIAGEN, Germany). RNAs were quantitated using either a 
Nanodrop 2000 (Thermo scientific Inc. USA) or Agilent Bioanalyzer 2100 (Agilent 
Technologies, Santa Clara, CA).  
 
2.6.1 RNA extraction from primary gastric tissues 
Primary tissue samples were cut and weighed accordingly. Tissues were grind to fine 
powder with liquid nitrogen in a pre-cooled mortar and pestle. Tissue powder was lysed 
with 600 µl RLT buffer (with β-mercaptoethanol). The samples were spinned for 2 min at 
full speed. The lysed supernatant was then transferred directly into a QIAshredder spin 
column placed in a 2 ml collection tube and spinned for 2 min at full speed at room 
temperature. 600 µl of 70% ethanol were added to the homogenized lysate and mixed 
well. Subsequently, samples were transferred to RNeasy spin column and centrifuged for 
15 sec at 8000 g. After discarding the flow-through, 700 µl Buffer RW1 was added to the 
RNeasy spin column, and centrifuged for 15 sec at 8000 g to wash the spin column 
membrane. Subsequently, 500 µl buffer RPE was added to the column and centrifuged 
for 2 min at 8000 g (twice). 30-50 µl RNase free water was then added to the column to 
elute RNA.  
 
2.6.2 RNA extraction from cultured cells 
Briefly, frozen cell pellets were lysed with 600 µl RLT buffer (with β-mercaptoethanol). 




collection tube and spinned for 2 min at full speed at room temperature. 600 µl of 70% 
ethanol were added to the homogenized lysate and mixed well. Subsequently, samples 
were transferred to RNeasy spin column and centrifuged for 15 sec at 8000 g. After 
discarding flow-through, 700 µl Buffer RW1 was added to the RNeasy spin column, and 
centrifuged for 15 sec at 8000 g to wash the spin column membrane. Subsequently, 500 
µl buffer RPE were added to the column and centrifuged for 2 min at 8000 g (twice). 30-









2.7 RLM-RACE (RNA-Ligase Mediated Rapid Amplification of cDNA Ends)  
RLM-RACE was performed using the FirstChoice
®
 RLM-RACE kit (Applied 
Biosystems, USA) following manufacturer‘s instruction. 
 
2.7.1 5' RACE 
10 µg of total RNA was first treated with 2 µl Calf Intestinal Alkaline Phosphatase (CIP) 
and incubated at 37°C for one hour to remove 5‘ phosphate groups, followed by Tobacco 
Acid Pyrophosphatase to remove 5‘ cap structures. After RNA linker ligation, mRNA 
transcripts were reverse transcribed using M-MLV reverse transcriptase (Applied 
Biosystems, USA). To amplify first strand cDNAs, outer 5‘ PCR was performed using 5‘ 
RACE outer primers (provided in kit) and a SLC1A2 exon 3 primer 
(ACACACTGCTCCCAGGATGA) with SuperTaq™ Plus polymerase (Applied 
Biosystems, USA). Subsequently, inner 5‘ PCR was performed using a 5‘ RACE inner 
primer (provided in kit) and a SLC1A2 exon 2 primer 
(AGCCAAGATGACTGTCGTGCATTC). Typical PCR reaction cycle consists of the 
following steps: denaturation at 94°C for 3 min, followed by 35 cycles of 94°C for 30 sec, 
annealing at the required temperature for 30 sec or its variable depending on the product 
size and 72°C for 1-2 min and final extension at 72°C for 7 min. After gel electrophoresis, 




 (Invitrogen, USA) 
vectors (see below for details). Purified plasmid DNAs were sequenced bi-directionally 
on an ABI 3730 automated sequencer (Applied Biosystems, USA). A minimum of 5 





2.7.2 3' RACE  
Briefly, 1 µg of total RNA was reverse transcribed using a 3‘RACE adaptor and reverse 
transcriptase provided in the kit. To amplify first strand cDNAs, outer 3‘ PCR was 
performed using 3‘ RACE outer primers and a SLC1A2 exon 1 primer 
(TTGAGGCGCTAAAGGGCTTACC) with SuperTaq™ Plus polymerase (Applied 
Biosystems, USA). Subsequently, inner 3‘ PCR was performed using a 3‘ RACE inner 
primer (provided in kit) and a separate SLC1A2 exon 1 primer 
(CAGACCATGGCATCTACGGAAGG). After gel electrophoresis, PCR bands of 




 (Invitrogen, USA) vectors. 
Purified plasmid DNAs were sequenced bi-directionally on an ABI 3730 automated 
sequencer (Applied Biosystems, USA). A minimum of 5 independent colonies were 





2.8 Semi-quantitative reverse-transcription PCR (RT-PCR) 
GC RNAs were reverse transcribed by SuperScript II reverse transcriptase enzyme using 
oligo-dT (T18) primers (Invitrogen, USA). To detect CD44-SLC1A2, RT-PCR was 
performed using forward primers to CD44 exon 1 (CCATGGACAAGTTTTGGTGGCA) 
and reverse primers to either SLC1A2 exon 3 (GTATATCCCCTGGGAAGGCT); exon4 
(CAGCTGCTTCTTGAGCTTGGGA); exon 5 (AAGCAGGCTTGGACAAGGTT) or 
exon 6 (CTCGTTCAACAGAGAGACAACAGC). Products were resolved by gel 
electrophoresis and bands of interest were excised and cloned for subsequent analysis. To 
evaluate wild-type CD44 and SLC1A2 expression independently of CD44-SLC1A2, we 
used CD44 forward primer targeting exons 3-5 (Sense: 
AGTCACAGACCTGCCCAATGC; antisense: TGCTGTCTCAGTTGCTGTAGCA); 
SLC1A2 primers targeting exon 1 (Sense: ATCGCCTGCAAATCCCCAGC; antisense: 
TGCCACCTGTGCTTTGCTGC). GAPDH was used as equal loading control (Sense: 
GCTCTCCAGAACATCATCCCTGC; antisense: 
TCTAGACGGCAGGTCAGGTCCAC). Standard PCR was performed in a 50 µl 
reaction using Bio-rad Tetrad 2 thermal cycler (Biorad, USA).  Each reaction included 25 
µl GoTaq® Hot Start Colorless Master Mix  (2X Colorless GoTaq® Reaction Buffer (pH 
8.5), 400 μM dATP, 400 μM dGTP, 400 μM dCTP, 400 μM dTTP and 4 mM MgCl2) 
(Promega, USA), 2 µl of 10 µM forward primer, 2 µl of  10 µM antisense primer, 2 µl  
template DNA and 19 µl of RNase free water. PCR reaction cycle consists of the 
following steps: denaturation at 94°C for 3min, followed by 35 cycles of 94°C for 30 secs, 
annealing at the required temperature for 30 sec or its variable depending on the product 




2.9 Gel purification  
Extraction and purification of DNA was performed using QIAquick gel extraction kit 
(QIAGEN, Germany) following the manufacturer‘s protocol. Briefly, the DNA fragment 
was excised from the agarose gel with a scalpel and weighed accordingly. 3 volumes of 
Buffer QG were added to 1 volume of gel (100 mg ~ 100 µl) and incubated at 50°C for 
10 min to completely dissolve gel. After the gel slice has dissolved completely, 1 gel 
volume of isopropanol was added to the sample. Next, the sample mixture was 
transferred directly to a QIAquick spin column placed in a 2 ml collection tube and 
centrifuged for 1 min at maximum speed. The flow-through was discarded and 0.75 ml of 
buffer PE was added to wash the column and centrifuged again for 1 min (twice).  Finally, 





2.10 DNA cloning techniques for sequencing 




 (Invitrogen, USA) 
vectors for downstream sequencing analysis using TOPO TA Cloning® for sequencing 
kit ((Invitrogen, USA) following manufacturer‘s protocol.  
 
2.10.1 DNA ligation 
DNA TOPO ligation reaction was carried out in 6 µl of volume, containing 4 µl PCR 




vectors (Invitrogen, USA). The 
ligation reaction was incubated at room temperature for 5 min. 
 
2.10.2 Transformation 
2 µl of the TOPO ligation reaction was added to one vial of One Shot Mach1™-T1R 
Competent E.coli Cells (Invitrogen, USA) and incubated on ice for 30 min. The mixture 
was heated at 30 sec at 42
o
C and cooled immediately on ice for 2 min. 250 µl of S.O.C. 
medium (Invitrogen, USA) was added to the mixture and incubated with shaking 
(200rpm) at 37
o
C for 1 hour. After incubation, ¼ of the transformation reaction mixture 
was spread onto LB plate supplemented with 50 µg/ml kanamycin (Invitrogen, USA) 
and the plate was incubated at 37
o




2.10.3 Plasmid purification 
Plasmid DNA isolation was carried out using PureLink™ Quick Plasmid Miniprep Kit 
(Invitrogen, USA) for subsequent sequencing analysis. Briefly, One Shot Mach1™-T1R 
Competent E.coli Cells containing desired plasmid were cultured in antibiotics-
supplemented LB broth, shaked and incubated at 37
o
C for 4 hour (200rpm). After 
incubation, 1-3 ml bacterial culture was transferred to a 1.5 ml microcentrifuge tube and 
centrifuged for 15 min at 1500 g. 240 µl of resuspension solution was added to 
completely resuspend the pellets, 240 µl lysis buffer was added and incubated for 4 min 
at room temperature. Subsequently, 340 µl neutralization buffer was added and mixed 
gently. The mixture was immediately centrifuged for 10 mins at max speed to clarify the 
cell lysates. The supernatant was transferred to a spin column and centrifuged at room 
temperature at 10,000-14,000 g for 1 min. 650 µl of wash buffer was then added to wash 
the column. Finally, 50 µl of water was added to the center of the column to elute DNA. 






















2.11 DNA sequencing 
If direct PCR products were used for sequencing, Exonuclease I-Shrimp Alkaline 
Phosphatase (Exo-SAP) (Affymetrix, USA) was first added to the PCR samples to 
remove residual single-stranded primers and dNTPs. The mixture were incubated at 37°C 
for 1 hour and 72 °C for 15 min to inactive the enzyme activity.  
 
Exo-SAP treated PCR products or purified DNA were then used for cycle sequencing 
reaction using ABI PRISM
TM
 BigDye Terminator Cycle Sequencing Ready Reaction kit 
(Applied Biosystems Inc. USA). The 10 µl reaction mixture containing 2 µl of 5X 
sequencing buffer, 0.32 µl of 10uM forward primer, 0.32 µl of reverse primer, 2-4 µl 
DNA template, 1 µl Bigdye terminator 3.1 and RNase free water.   
 
The program for sequencing reaction was 10 sec at 96°C, 5 sec at 50°C, 4 min at 60°C 
for 30 cycles on the thermocycler. After the completion of cycles, the mixtures were 
purified using the ethanol precipitation method. Briefly, 4 µl of EDTA (62.5 nM) (Gibco, 
USA) and 30 µl pre-chilled pure ethanol was added to each sample. The solution was 
centrifuged for 40 min at 4000rpm at 4 
o
C and the supernatant was removed completely. 
The pellet was then washed by adding 90 µl of 70% pre-chilled ethanol. The samples 
were centrifuged for 20 min at 4000 rpm at 4 
o
C before being dried. Prior to sequencing, 
10 µl of Hi-Di Formamide (Applied Biosystems, USA) was added to the DNA pellet and 
the mix was then used for sequencing on ABI PRISM 3730 Genetic Analyzer (Applied 






2.12 Fiber-FISH  
SNU16 cells and control cells (normal lymphoblastoid CCL159) were grown in RPMI 
1640 enriched with 15% FBS, 1% PS and 1% L-Glutamine. 2-3ml of each cell 
suspension was centrifuged at 1200 rpm for 12 mins and then washed with 6 ml PBS 
twice. Pellets were diluted with PBS to a final concentration around 2-3 x 10
4
/ml. 10 µl 
of each cell suspension was spread on a poly-L-lysine (Sigma, USA) coated slide, air 
dried and then fitted into a Cadenza Coverslip according to manufacturer‘s 
recommendations (Thermo Shandon).  150 µl of freshly made lysis solution (5:2 70 mM 
NaOH:absolute Ethanol) was applied to the slides, followed by 150 µl of 96% Ethanol. 
Slides were air dried at room temperature, treated with 3:1 Acetic Acid:Ethanol Fixative 
for 5 mins and  dehydrated in Ethanol series (70%, 90%, and 100%) for 3 mins each. The 
FISH procedure was then applied. 
 
2.13 Long range genomic PCR 
CD44/SLC1A2 chromosomal inversions were detected using Qiagen LongRange PCR kit 
(QIAGEN, Germany) following the manufacturer's instructions. Briefly, 50 µl of reaction 
mixture was composed with 5 µl of 10X LongRange PCR buffer, 2.5 µl dNTP, 2 µl of 
forward primer at CD44 exon 1 (GAAGAAAGCCAGTGCGTCTC, positive strand), 2 µl 
of reverse primer at SLC1A2 intron 1 in the minimal breakpoint region 
(GAGGGCTGTCCTTAACGCCTAGC, negative strand), 0.4 µl LongRange PCR 
Enzyme Mix, 100 ng DNA template and RNase-free water.  
PCR conditions for 0.1–10 kb sample were: initial activation at 93°C for 3 min, followed 




extension 1 min/kb 68°C (Use an extension time of 1 min per kilobase DNA for genomic 
DNA) and end of cycle run at 4°C. 
 
PCR conditions for >10kb sample were: initial activation at 93°C for 3 min, followed by 
first 10 cycles of 93°C for 15 sec, annealing at the required temperature for 30 sec, 
extension for 1 min/kb 68°C (Use an extension time of 1 min per kilobase DNA for 
genomic DNA) and next 28 cycles of 93°C for 15 sec, annealing at the required 
temperature for 30 sec, extension for 1 min/kb +20 sec in each additional cycle at 68°C.  
 
2.14 Quantitative-RT PCR (qRT-PCR) 
SNU16 GC cells lines and 9 primary gastric tumors were selected for qRT-PCR analysis 
using Quantifast SYBR green PCR kit (QIAGEN, Germany) following manufacturer‘s 
instructions. T1, T2, T3 were group 1 gastric tumors which are 11p13 amplification 
negative and fusion negative; T4, T5, T6 are group 2 tumors which are 11p13 amplified 
but do not express CD44-SLC1A2; T7, T8, T9 were group 3 tumors expressing CD44-
SLC1A2 but are non-11p13 amplified.  Briefly, 2 µg RNA was reverse transcribed by 
SuperScript III reverse transcriptase enzyme using oligo-dT (T18) primers (Invitrogen, 
USA). 25 µl of q-PCR reaction was prepared with 12.5 µl 2X QuantiFast SYBR Green 
PCR Master Mix, 1 µl of forward primer, 1 µl reverse primer,  2 µl template cDNA and 
RNase-free water.  Primers used were: Fusion forward primer targeting CD44 exon 1 
(TTCGGTCCGCCATCCTCGTC) and reverse primer targeting SLC1A2 exon 2 
(CACTTCCACCTGCTTGGGCA); SLC1A2 exon 1 forward primer  
(GCCCGTTGAGGCGCTAAAGG) and reverse primer 




(CCACCCAGAAGACTGTGGATGG) and reverse primer 
(CACTGACACGTTGGCAGTGG).  qPCR reaction was carried out using cycling 
program outlined below:  initial activation at 95ºC for 5 min,  35 cycles of denaturation  
for 10 sec  at 95ºC and Combined annealing/ extension for 30 sec at 60ºC. Samples were 
analyzed using Applied Biosystem 7900HT system (Applied Biosystems, USA).  
 
To avoid nonspecific binding of SYBR Green to any double strand DNA or primer 
dimmers, primers were carefully designed to give a product around 200 base pairs. 
Experimental reports including amplification analysis, melting curve analysis and 





2.15 Protein isolation 
Total proteins, cytoplasm proteins and membrane phase proteins were extracted from 
gastric cancer cells to serve different experimental purposes.   
 
2.15.1 Total protein isolation from cell lysates 
Briefly, cells (1-5x10
6
 /sample) were harvested by removing cell culture medium. The 
cell pellets were rinsed with 1X PBS and centrifuged to remove the supernatant. 1X 
RIPA buffer containing phosphatase inhibotors (Tris-HCl 1 M pH 7.5, 10% NP-40, 10% 
Na-deoxycholate, 500 mM NaCl, 0.5 M EDTA) were added to lyse the cells for 1 hour at 
4ºC. The supernatant was transferred to a clean tube after centrifugation at 13,000 g at 
4ºC and stored at -80ºC until used. Protein concentration was determined before storage.  
 
 
2.15.2 Membrane phase extraction from cell lysates 
Cells (1-5x10
6
 /sample) pellets were resuspended with lysis buffer (10 mM Tris.Cl pH 
7.5, 150 mM NaCl, 1%Triton X-114) at 4ºC for 1 hour before centrifuge at 800 g for 15 
min at 4ºC. Supernatants were transferred to a new tube and incubated at 30ºC for 5-10 
min until condensation occurred. The samples were then centrifuged at 300 g at room 
temperature for 5 min. The integral membrane proteins were in the detergent phase at the 
bottom of the centrifuge tube, while the supernatant containing the cytoplasm proteins 




The two phases were then collected separately and necessary amount of either Triton X-
114 or base buffer (without Triton X-114) were added to obtain equal volume and 
approximately the same chemical concentration for both samples.  
 
2.15.3 Determination of protein concentration  
Protein concentration was measured using DC™ Protein Assay kit (BIO-RAD, USA). 
Briefly, 1 ml sample mixture was prepared (Including 100 µl reagent A, 100 µl water, 
800 µl reagent B). Four dilutions of a protein standard were prepared using BSA. Protein 
samples were added to the mixture and incubated at RT for 15 min in dark. Protein 
concentration was measured by Lowry methods using Pharmacia Biotec Ultrospec 3000 





2.16 Western blotting 
Western blotting was used for desired protein detection. Protein samples were prepared 
by the methods described in Protein Isolation chapter. 
 
2.16.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The SDS-PAGE gel was carried out using a Mini-PROTEIN Electrophoresis System 
(BIO-RAD, USA). The gels were prepared dependent on different concentrations in order 
to detect proteins of various molecular weights. Briefly, separating gels were prepared by 
mixing appropriate amount of 30% acrylamide/bisacrylamid solution (37.5:1, BIO-RAD, 
USA) with water, 1.5 M Tris Cl (pH 8.8), 10% SDS, 10% fresh ammonium persulfate 
(APS) (BIO-RAD, USA) and TEMED (BIO-RAD, USA). Propanol was covered on top 
of the separating gel. After polymerization, overlay was decanted and a 4% stacking gel 
was poured. 2 ml of 4% stacking gel was prepared by mixing 1.35 ml water, 0.33 ml 30% 
acrylamide/bisacrylamid solution, 0.5 ml Tris.Cl ( pH 6.8), 100 µl 10% SDS, 100 µl APS 
and 4 µl TEMED. Comb was inserted correctly and allowed to polymerize completely 
before running. 
 
Unless stated otherwise, 60 µg of protein for each sample was resolved on SDS-PAGE 
gels under denaturing conditions. The protein samples were mixed with 3X loading 
buffer (150 mM Tris HCl pH 6.8, 6% SDS, 0.3% bromophenol blue, 30% glycerol and 
300 mM mercap (add fresh)) and boiled in 100ºC heat blocker for 5 min. samples were 
then loaded and the gel was run under 80 volts till the dye reached the resolving gel and 
thereafter at 120 V till satisfactory protein separation was observed. Kaleidoscope Protein 




2.16.2 Gel transfer 
The separated protein was electrophorectically transferred onto pre-activated PVDF 
membranes (BIO-RAD, USA). The polyacrylamide gel was rinsed in transfer buffer (25 
mM Tris,192 mM Glycine, 0.1% SDS, 20% methanol), placed in-between layers of filter 
paper and membrane of the same size of the gel, inserted into the plastic holder with 
sponge soaked in transfer buffer. The air bubbles were removed by rolling with a glass 
pipet. The transfer was performed in transfer buffer at 100 V for 1 hour at 4ºC.  
 
2.16.3 Immunoprobing and detection 
The membranes were incubated with anti- SLC1A2/EAAT2 primary antibody (1:500, 
Cell Signaling Technology, Danvers, MA) for two hours at room temperature, followed 
by anti-rabbit HRP-conjugated secondary antibody (Cell Signaling Technology, MA) for 
another 2 hours. The membranes were washed extensively in PBST washing buffer (1X 
PBS and 0.1% Tween-20). For equal loading of samples, the blots were probed with anti-
α-tubulin primary antibody (Cell Signaling Technology, MA) and then anti-rabbit HRP-
conjugated secondary antibody (Cell Signaling Technology, MA). The membrane was 
then washed before incubating with the Pierce ECL Western Blotting Detection System 
(Thermo Scientific, USA) by mixing equal volumes of the two reagents for 5 min and 
exposed to Hyperfilm X-ray films (Kodak, USA) at various desired time lengths in the 




2.17 Immunofluorescence staining 
Cells were fixed with 3.7% formaldehyde (prepared in 1xPBS) and permeabilised with 
0.1% Triton-X 100 (prepared in 1xPBS), then deposited on microscopy slides in a 
cytospin centrifuge. After 3 times washes with 1X PBS, cells were blocked with 1% BSA. 
Subsequently, Fluorescent labeling was performed using the anti-SLC1A2 antibody (Cell 
Signaling Technology, MA) as primary for 2 hour and FITC-conjugated as secondary 
antibody (Sigma-Aldrich, Singapore) for 2 hour. Nikon Eclipse TE2000-U microscope 
was used to analyze the fluorescent microscopy staining, and images were captured using 
a Leica DC 300F camera (Nikon, Japan).  
 
2.18 siRNA transfection 
GC cells were stably transfected with either specific siRNAs targeted to the CD44-
SLC1A2 fusion site (siRNA1:  CGCAGAUCGUGCCAACAAUUU; siRNA2:  
GCACAUCGUGCC AACAAUAUU) (100 nM, custom siRNA siGENOME with 





 transfection reagent (Applied Biosystem, USA) in Opti-MEM Medium 
(Invitrogen, USA) following the manufacturer's protocol. Briefly, appropriate number of 
cells was resuspended and cultured in 2.3 ml normal growth medium in a 6 well plate 




 transfection reagent was mixed well with 
100 µl of Opti-MEM medium and incubated at RT for 10 mins. Meantime, 7.5 µl of 10 
µM siRNA was also mixed with 100 µl of Opti-MEM medium. After 10 min incubation, 
the two solutions were mixed together and incubated for 10 min at RT to allow 




cells were incubated at 37ºC for 48 hour. Stable transfectants were selected with 
puromycin for 4 weeks. 
 
For wild-type SLC1A2 siRNAs transfection, GC cells were transfected with specific non-
overlapping siRNAs targeted either to SLC1A2 exon 1  or SLC1A2 downstream regions 
(100 nM, custom siRNA siGENOME with SMART selection, Dharmacon) or negative 




 transfection reagent (Applied 





2.19 CD44-SLC1A2 DNA cloning and overexpression 
The full length coding regions of CD44–SLC1A2 cDNA were inserted into the pEGFP-
N1 vector (Clontech， USA) and transformed into One Shot Mach1TM-T1R Competent 
E.coli Cells as described above. Plasmid DNA was purified and control vectors or fusion-
GFP vectors were introduced into gastric cells using SuperFect® Transfection Reagent 
(QIAGEN, Germany). Briefly, the day before transfection, 2–8 x 105 cells were seeded in 
2 ml appropriate growth medium in 6-well plates and incubated under normal growth 
conditions. On the day of transfection, 2 μg DNA were diluted with 100 µl Opti-MEM 
medium. 20 μl SuperFect Transfection Reagent was then added to the DNA solution and 
incubated for 5-10 min at RT to allow transfection-complex formation. While complex 
formation took place, cells were washed with PBS and 500 µl normal cell growth 
medium were added to the reaction tube containing the transfection complexes. The 
complexes were carefully mixed and immediately transferred to the cells. Cells were 
incubated with the transfection complexes for 2–3 h under their normal growth conditions 
before changing the medium to fresh cell culture medium. Cells were then incubated for 















2.20 In vitro cell assays 
 
2.20.1 Cell proliferation assay  
Cell proliferation assays were performed using a CellTiter96® Aqueous Nonradioactive 
Cell Proliferation Assay kit (MTS) (Promega, USA) following the manufacturer's 
instructions. Briefly, gastric cells (1000-2000 cells per well) were cultured overnight in 
96-well plate in 100 µl of normal growth medium at 37ºC. 20 µl of MTS reagents were 
added into each well and mixed well with the culture medium. The mixture was 
incubated for 3 hours at 37ºC in dark. After 3 hours incubation, proliferation rates were 
measured at 490 nm using a PerkinElmer plate reader (PerkinElmer, USA). Each assay 
was performed in triplicate, and the results were averaged over three independent 
experiments. 
 
2.20.2 Cell invasion assays 




 invasion chambers with 
8 µm pore filter inserts (BD Bioscience, USA). Briefly, 0.5 ml of normal growth medium 
were added to both the interior of the inserts and bottom of wells for rehydration for 2 
hours. After rehydration, the medium was carefully removed without disturbing the layer 
of Matrigel™ Matrix on the membrane. Subsequently, 0.75 ml of FBS was added as 
chemoattractant to each well of the Companion Plate. The chambers and control inserts 
were carefully transferred to the wells with chemoattractant without causing air bubbles. 
Immediately, 2.5x10
4
 cells in 0.5 ml normal growth medium were added to the 24-well 




culture incubator, at 37
o
C, 5% CO2 atmosphere. After incubation, the invading cells were 
counted using light microscopy.  
 
2.20.3 Soft agar assays 
Base layers constituted of 0.5% Gum Agar in 1x McCoy‘s 5A and 10% FBS were poured 
into 6-well plates and allowed to set. Meantime, appropriate number of cells was 
resuspended in normal growth medium. 10 µl of cell suspension was mixed well with 1.5 
ml top agar constituted of 0.3% Gum Agar in 1x McCoy‘s 5A and 10% FBS and plated 
to each well immediately.  The agar was allowed to set for at least 30 min before 2 ml of 
normal growth medium was seeded on top of the solidified base layer.  The plates were 
incubated  at 37°C in humidified incubator for 3-4 weeks, during which plates were fed 
drop-wise with complete media. After 3-4 weeks, plates were photographed using the 
Kodak GL 200 System (EpiWhite illumination) (Kodak, USA). Each assay was 
performed in triplicate, and the results were averaged over three independent experiments. 
 
2.20.4 Glutamate assays  
Gastric cancer cells and primary tissues were lysed in glutamate assay buffer and 
glutamate concentrations were determined using a Glutamate Assay Kit (BioVision, 
USA).  Briefly, cells or primary tissues were homogenized in 100 µl assay buffer 
centrifuged to remove insoluble material at 13,000 g for 10 minutes. Subsequently, 10 ul 
of each serum samples were added directly to each well with duplicates. Glutamate 
standard were prepared in duplicate to generate 0, 2, 4, 6, 8, 10 nmol/well standard. A 




glutamate as a specific substrate leading to proportional color development. The plate 
was then measured at 450 nm in a Tecan infinite M200 microplate reader (Tecan, USA).  
 
2.20.5 Drug treatments 
For cisplatin treatments, appropriate number of cells was seeded into 96 well plates after 
siRNA transfection. Subsequently, cisplatin or 5-FU at increasing dosages were added (0-
1 mM) to respective wells. Cells were subjected to MTS proliferation assays (described 
above) after 48 hours of drug treatment. Each assay was performed in triplicate, and the 




2.21  Copy number analysis (Affymetrix) 
Affymetrix SNP6 arrays were processed using Affymetrix GTC 4.0 software and tumor 
profiles were normalized against a matched normal reference. The data was visualized 
using Nexus 5.0 software (Biodiscovery, USA). A Rank Segmentation algorithm, a 
variation of the segmentation method based on Circular Binary Segmentation (S1) was 
used to segment the copy number data across the genome. 
 
2.22 Gene expression analysis 
Gene expression data is available from the Gene Expression Omnibus under access 
number GSE15460. Gene expression profiles (Affymetrix U133P2 arrays) were 
normalized using the MAS5 algorithm. Comparisons between CD44 and SLC1A2 
expression values was performed on a subset of 45 samples for which gene expression, 
copy number information, and CD44-SLC1A2 gene fusion status was available. 
Unsupervised clustering was based on all probesets after removing the bottom 25% of 
probes with the lowest interquantile range. Hierarchical clustering and Wilcoxson signed 
rank tests were performed using R software 2.9.0. FDR q value calculations were 
calculated using the R package ‗qvalue‘. GO analysis was performed using the DAVID 
database (S2, S3). 
 
2.23 Statistical analysis 
Experiments were assessed by Student‘s unpaired t test, with the exception of the 
tumor/normal glutamate measurements where a paired t-test was used. P values <0.05 




Chapter III: RESULTS 
 
3.1 Analysis of GC copy number alterations identifies recurrent SLC1A2/EAAT2 
genomic breakpoints  
Previous cytogenetic and chromosomal studies have established that individual GCs often 
exhibit high degrees of karyotypic complexity (Espinoza et al., 1999; Tay et al., 2003). 
Motivated by the intimate link between copy number alterations (CNAs), chromosomal 
rearrangements and gene fusions (Bignell et al., 2007; Persson et al., 2009), we 
hypothesized that a detailed fine-scale survey of genomic CNAs might reveal potential 
genes disrupted by fusion events in GC.   
 
3.1.1 Validation of Agilent 244k aCGH data 
Using high density microarrays (Agilent Human 244k), we profiled a discovery cohort of 
133 GCs (106 primary tumors and 27 cell lines). Validation of the microarray data was 
achieved by comparing the CNA profiles to earlier studies. We successfully re-identified 
many previously known genomic aberrations in GC, including amplifications in c-Myc, 
HER2, RAB23, and deletions in PTEN (Fig. 3.1) (Hou et al., 2008; Mitsui et al., 2007; 






Figure 3.1. MYC, ERBB2, RAB23, and PTEN genomic aberrations in SNU16, N87, 
HS746T and TMK1 cells detected by Agilent 244k aCGH 
A. Copy number amplification of the MYC oncogene detected in SNU16 cells. X-axis,  
log2-transformed smoothened copy number values averaged over a 0.1Mb moving 
window. Y-axis, physical genomic coordinates along chromosome. The black arrows 
point to the respective genes. Vertical Blue dashed lines indicate copy number values of 2 
(Log-transformed copy number = 0).  
B. ERBB2 amplification in N87 GC cells. X-axis, log2-transformed smoothened copy 
number values averaged over a 0.1Mb moving window. Y-axis, physical genomic 
coordinates along chromosome. The black arrows point to the respective genes. Vertical 





Figure 3.1. MYC, ERBB2, RAB23, and PTEN genomic aberrations in SNU16, N87, 
HS746T and TMK1 cells detected by Agilent 244k aCGH  
C. RAB23 amplification in HS746T GC cells. X-axis, log2-transformed smoothened copy 
number values averaged over a 0.1Mb moving window. Y-axis, physical genomic 
coordinates along chromosome. The black arrows point to the respective genes. Vertical 
Blue dashed lines indicate copy number values of 2 (Log-transformed copy number = 0). 
D. PTEN deletion in TMK1 cells. X-axis, log2-transformed smoothened copy number 
values. Y-axis, physical genomic coordinates along chromosome. The black arrows point 
to the respective genes. Vertical Blue dashed lines indicate copy number values of 2 




3.1.2 Breakpoint analysis using aCGH data reveals recurrent SLC1A2/EAAT2 
genomic breakpoints 
To nominate potential fusion genes, we employed a technique called Genomic 
Breakpoint Analysis (GBA), previously used to identify fusion genes in leukemia 
(Kawamata et al., 2008). In this strategy, putative chromosomal breakpoints were 
identified by examining closely-spaced microarray probes displaying prominent 
transitions in copy number status, from low to high copy number or vice versa. In total, 
we identified 90 genomic breakpoints occurring in genes such as CALCR, PERLD1, and 
CKAP5 (intragenic breakpoints, Table 3.1). The highest recurrence rate among the 
breakpoints was 3% and most breakpoints occur only in one sample. This is probably due 
to the high genomic complexity and clonal heterogeneity of GC. A representative 
example of a genomic breakpoint, occurring in the CALCR gene, is shown in Figure 3.2A.  
 
For the majority of genes exhibiting genomic breakpoints in multiple samples (eg CRKRS, 
TTC25), the breakpoints were randomly scattered throughout the gene body consistent 
with a random breakage model of chromosomal amplification. However, four GCs out of 
133 (three primary tumors and one cell line - GC980417, GC20021048, GC2000038 and 
SNU16) exhibited genomic breakpoints specifically localized to the 5' region of the 
SLC1A2/EAAT2 gene, encoding a high affinity glutamate transporter (hence after referred 




Table 3.1: List of genes exhibiting genomic breakpoints 
 
Gene Location Genomic Event Tumor/ Cell Line ID 
CRKRS 17q12 Focal Amplification 
90929219,2000484,73499299
, 2001140 
SLC1A2 11p13 Focal Amplification 
980417,  20021048, 2000038, 
SNU16 
ZNFN1A3 17q21 Focal Amplification 
20020164,9874831, 
54115380, YCC9, N87 
GSDML 17q12 Focal Amplification 90929219, 54115380 
WIRE 
17q21.1-
17q21.2 Focal Amplification 2000484,  2001140 
SMARCE1 17q21.3 Focal Amplification 2000484, 2001140 
CKAP5 11p11.2 Focal Amplification 2000763,  2000563 
PERLD1 17q12 Focal Amplification 20020164, 54115380 
LDLRAD3 11p13 Focal Amplification 20021048, 20020448 
TACC2 10q26 Focal Amplification 980417, 20020700 
KIAA0319 14q13.2 Focal Amplification YCC9, N87 
TTC25 17q21.2 Focal Amplification YCC9, N87 
CDH26 20q13.33 Deletions MKN74,MKN28 
TRERF1 6p21.1-p12.1 Focal Amplification YCC1, YCC6 
PEX7 6q23.3 Amplification 990020 
KIF 6 6p21.2 Amplification 990428 
PDSS2 6q21 Focal Amplification 980447 
POPDC3 6q21 Focal Amplification 980447 




ELF5 11p13-p12 Focal Amplification 2000038 
RASSF8 12p12.3 Focal Amplification 990428 
DYM 18q12-21.1 Focal Amplification 990221 
LOC126248 19q13.11 Focal Amplification 980255 
CAT 11p13 Focal Amplification 20021048 
c13orf24 13q22.1 Amplification 980021 
BCAT1 12p12.1 Focal Amplification 980024 
PDE1A 2q32.1 Amplification 980024 
LST-3TM12 12p12.2 Focal Amplification 980024 
IDH1 2q33.3 Amplification 20020164 
ZNF403 17q12 Focal Amplification 20020164 
SOCS7 17q12 Focal Amplification 20020164 
RAB3IP 12q14.3 Amplification 20020563 
RFFL 17q12 Focal Amplification 20020700 
KLHL10 12q14.3 Focal Amplification 20020700 
CALCR 17q12 Focal Amplification 20020700 
MULK 17q21.2 Amplification 2001098 
DSCR3 21q22.2 Focal Amplification 2000710 
TP53I11 11p11.12 Focal Amplification 2000763 
FLJ46154 11p14.1 Amplification 2000763 
KIF14 1q32.1 Amplification 90929219 








C17ORF63 17q11.2 Amplification 9874831 
TNKS 8p23.1 Focal Amplification 42761681 
FBXL20,  17q12 Focal Amplification 54115380 
PPARBP 17q12-q21.1 Focal Amplification 54115380 
TSHZ2 20q13.2 Deletions 73499299 
SLC24A3 20p13 Amplification 73499299 
SCARA5 8p21.1 Amplification 20020448 
RC74 8p21.1 Amplification 20020448 
MTSS1 8p22 Focal Amplification 20020448 
PROK2 3p13 Deletions 37175329 
ST7 7q31.1-q31.3 Focal Amplification 20020070 
WNT2 7q31.2 Focal Amplification 20020070 
STARD3  17q11-q12 Focal Amplification 2001140 
CCR7 17q12-21.2 Focal Amplification 2001140 
PREP 6q16.3-q22.1 Focal Amplification 980447 
RPA2 1p35.1 Amplification YCC9 
RPAIN 17p13.2 Amplification FU97 
SYN 22q12.3 Deletions SCH 
LRP1B 2q21.2 Focal deletions SCH 
DGKG 3q27.3 Deletions SCH 
PDE4D 5q12 Focal deletions SCH 
CCDC91 12p11.22 Deletions MKN74 
COL24A1 1q22.3 Amplification MKN28 




MYO18A 17q11.2 Amplification MKN1 
STK38L 12p11.23 Focal Amplification MKN1 
SORT1 1p21.3-p13.1 Focal Amplification MKN45 
CADPS2 7q31.3 Focal Amplification MKN45 
MAP2K4 17p11.2 Deletions MKN45 
KIF18A 11p14.1 Focal Amplification MKN45 
TBC1D22A 22q13.3 Deletions MKN45 
PEPD 19q12-q13.2 Focal Amplification TMK1 
PTEN 10q23.3 Focal deletions TMK1 
LSM14A 19q13.11 Focal Amplification TMK1 
ATF7IP2 16p13.13 Amplification YCC7 
DNM2 19p13.2 Amplification YCC7 
WDR40A 9p13.3 Amplification YCC7 
ZCCHC7 9p13.2 Amplification YCC7 
MN1 22q12.1 Amplification YCC7 
FLJ33814 22q12.1 Amplification YCC7 
EMID1 22q12.2 Amplification YCC7 
NF2 22q12.2 Amplification YCC7 
RBM9 22q13.1 Amplification YCC7 
CPE 4q32.3 Deletions SNU1 
LRBA 4q31.3 Deletions SNU5 
ATE1 10q26.13 Focal Amplification SNU16 
CLCA4 1p31-p22 Deletions YCC2 


















Figure 3.2. Genomic breakpoint analysis in GC  
A. Representative example of a genomic breakpoint. aCGH profile of GC tumor 
GC20020700 exhibited a genomic breakpoint in the CALCR gene on Chr 7q12. X-axis - 
physical chromosomal coordinates.  Y-axis - log2-transformed smoothened values (i.e. 0 
indicates copy number equals to 2). The red arrow indicates the breakpoint of interest. 
The black arrow below represents the CALCR gene pointing in a 5‘-3‘ direction. Each dot 




















Figure 3.2. Genomic breakpoint analysis in GC  
B. Genomic breakpoint analysis in GC identified recurrent breakpoints in the 5‘ region of 
SLC1A2 in four GCs (3 primary tumors and 1 cell line - GC2000038, GC980417, 
GC20021048, SNU16). Red arrows indicate the breakpoints of interest. X-axis - physical 
chromosomal coordinates.  Y-axis - log2-transformed smoothed values (i.e. 0 indicates 
copy number equals to 2). The black arrow below represents the SLC1A2 gene pointing 
in a 5‘-3‘ direction. Each dot represents a microarray probe. The red bar below indicates 





3.1.3 Validation of SLC1A2 genomic breakpoints 
Notably, 11p13-15 where SLC1A2 are located has been described as a frequent site of 
genome rearrangement in gastric and esophageal cancers (Rodriguez et al., 1990). 
Therefore, we performed Spectral Karyotyping (SKY) to identify possible genomic 
rearrangements in SNU16. SKY analysis confirmed the presence of at least two 11p13-
11p14 genome rearrangements in SNU16 cells, one involving fusion of Chromosome 1 
with Chromosome 11 at band 11p13-14, and the second involving a complex 
chromosomal scenario with rearrangements joining chromosomes 5, 10 and 11 (Fig. 
3.3A). These results confirmed previous findings that 11p13-15 is a frequent site for 
genomic aberrations.  
 
To validate the SLC1A2 breakpoint region, we performed Fluorescence in situ 
Hybridization (FISH) analysis using fosmid probes mapping upstream or downstream to 
the putative breakpoint (WI2-67O19 and WI2-1928P9).  Supporting the aCGH data, the 
WI2-67O19 upstream probe (35384118-35427600) covering the first exon of SLC1A2 
showed 4 signals in SNU16 nuclei (Fig. 3.3C, left), confirming previous studies which 
reported SNU16 is a naturally tetraploid cell line (Park et al., 1990). In contrast, the 
downstream WI2-1928P9 probe (35323126-35359663) located at SLC1A2 intron 1 
showed multiple hybridization signals (>50 copies) indicating a high level amplification 



















Figure 3.3. Validation of unbalanced genomic break in 11p13 SLC1A2 region in 
SNU16 cells 
A. SKY analysis of SNU16 cells revealed an unbalanced chromosomal rearrangement 
affecting 11p13-11p14. Left, SKY showed chromosome aberration t(1;11)(?;p14), 
indicating a rearrangement of chromosome 1 with chromosome 11 at bands 11p14. Right, 
SKY identified the complex chromosomal aberration t(5;11;10) with rearrangements 
joining material from three different chromosome 5, 11, 10.  
B.   Genomic organization of the SLC1A2 gene. Vertical bars represent SLC1A2 exons, 
connected by intervening introns. Total length of the SLC1A2 gene is 168 Kb. Red bar: 
minimal common recurrent breakpoint region in SLC1A2 intron 1 (15-24 kb).  
C.  FISH Validation of SLC1A2 breakpoints. Probes WI2-67O19 (red) covered SLC1A2 





3.2 SLC1A2 breakpoint characterization reveals a CD44-SLC1A2 gene fusion  
 
3.2.1 Identify 5’ fusion partners to SLC1A2 
Integrating the SLC1A2 breakpoint regions from the aCGH and the FISH data, we 
defined a 15-24 kb minimal common breakpoint window in the SLC1A2 first intron 
(Figure 3.2B and 3.3B, red bar). We hypothesized that chromosomal aberrations affecting 
this region may disrupt the SLC1A2 gene resulting in potential fusion partners. To test 
this possibility, we performed 5‘ RNA Ligase-Mediated Rapid Amplification of cDNA 
Ends (RLM-RACE) to characterize SLC1A2 transcript sequences upstream to SLC1A2 
exon 2.  A 250 bp 5‘ RACE product was identified in breakpoint positive SNU16 cells, 
but not in other GC cell lines without SLC1A2 breakpoints (AGS, YCC1, YCC9 and N87) 
(Fig. 3.4A).   
 
Sequencing of the amplified SNU16 RACE product revealed a CD44-SLC1A2 fusion 
transcript, formed by the juxtaposition of CD44 exon 1 to SLC1A2 exon 2 (Fig. 3.4B). To 
validate the 5‘ RACE results, we designed combination sets of PCR primers targeting 
CD44 exon 1 (forward primer) and SLC1A2 exons 3, 4, 5, 6 (reverse primers) to directly 
detect the fusion by reverse-transcription PCR (RT-PCR). CD44-SLC1A2 transcripts 
were detected in SNU16 cells, but not in other GCCLs nor in commercially available 
normal gastric tissue (NG) (Fig. 3.4C-D). These results demonstrate the existence of a 






We further confirmed the expression of a complete ~1.6 kb CD44-SLC1A2 transcript in 
SNU16 cells using RT-PCR primers targeting CD44 exon 1 and SLC1A2 exon 11 (the 
last SLC1A2 exon) (Fig. 3.4E), with two potential translation start sites (Fig. 3.4B, 
underlined) . 
 
All of the SLC family gene fusions identified to date involve the SLC gene at the 5' end 
of the fusion, such as SLC45A3-BRAF in prostate cancer and SLC34A2-ROS1 in non-
small-cell lung cancer.  So in complement to the 5‘ RACE analysis, we performed 3' 
RACE from exon 1 of SLC1A2 to determine if there is a productive 3' partner for 
SLC1A2. However, 3‘ RACE analysis in SNU16 cells studying transcripts downstream of 
SLC1A2 exon 1 did not identify any additional fusion partners besides wild-type SLC1A2 
transcripts (Fig. 3.4F). Thus, at this point, we have no evidence suggesting that the 
SLC1A2 5‘ end is involved in another productive fusion in SNU16. 
 
CD44 and SLC1A2 lie adjacent to each other on chromosome 11p13, being separated by 
only ~19kb (Fig. 3.4G). The two genes are transcribed towards each other and lie on 
opposite strands, indicating that they possess distinct promoters. Because chimeric 
transcripts caused by read-through transcription typically involve adjacent genes on the 
same strand (Akiva et al., 2006; Wang et al., 2007), it is unlikely that the CD44-SLC1A2 
fusion transcripts are created by a read-through event. We thus hypothesized that the 







Figure 3.4. Detection of fusion CD44-SLC1A2 in SNU16 cell line 
A. 5‘ SLC1A2 RLM-RACE in GC cell lines (AGS, SNU16, YCC1, YCC9, N87). PCR 
mix without sample input was used as a negative control (-ve).  
B. Sequencing of the 5‘ RACE gene product identified a fusion of CD44 exon 1 to 
SLC1A2 exon 2. Blue colored sequence indicates the CD44 exon 1. Red sequence shows 
partial exon 2 of SLC1A2. ATG sites are underlined.  
C. RT-PCR confirmed the exon joining between CD44 and SLC1A2 in SNU16 cells. 4 
RT-PCR reactions were conducted using a forward primer in exon 1 of CD44 indicated 
by the blue horizontal arrow, and 4 different reverse primers in exons 3, 4, 5, 6 of 





Figure 3.4. Detection of fusion CD44-SLC1A2 in SNU16 cell line 
D. RT-PCR screening of the CD44-SLC1A2 fusion in 42 gastric cancer cell lines and 
gastric normal cell lines. SNU16 (green) is the only cell line expressing the fusion. 
E. Left, RT-PCR analysis using a forward primer to CD44 exon 1 and reverse primer to 
SLC1A2 exon 11 (last exon) confirmed expression of a ~1.6 kb CD44-SLC1A2 fusion 
transcript in SNU16 cells. Right, PCR product sequencing confirmed a full length fusion 






















Figure 3.4. Detection of fusion CD44-SLC1A2 in SNU16 cell line 
F. Left, 3‘RACE analysis of SLC1A2 identified 2kb products in both AGS and SNU16. 
Right, sequencing of the 3‘ RACE products confirmed wild-type full length SLC1A2 
transcripts in both SNU16 and AGS cells. 
G. Predicted fusion pattern between CD44 and SLC1A2. Top, CD44 and SLC1A2 
chromosomal organization. Bottom, CD44-SLC1A2 relationship to CD44 and SLC1A2 




3.2.2 Confirmation of CD44-SLC1A2 chromosomal inversion in SNU16 
The close proximity of the CD44 and SLC1A2 genes makes it extremely challenging to 
validate the CD44/SLC1A2 genomic inversion using conventional FISH techniques, 
which have typical resolutions of 100 kb - 1 Mb.  In the current study, we used two 
different strategies to verify the presence of CD44/SLC1A2 genomic inversions in this 
region. First, we used fiber-FISH, a high-resolution method for genomic DNA mapping 
(Florijn et al., 1995). Fosmid probes Rp1-68d18 (35146316-35329998, covering the 
CD44 gene and a portion of the SLC1A2 gene, green signal) and Rp11-1148l23 
(35294107-35461767, covering the SLC1A2 gene only, red signal) were hybridized to 
SNU16 cells or normal lymphoblastoid CCL159 cells. In control CCL159 cells, a normal 
chromosome was observed and indicated by two distinct red and green probe signals 
lying adjacent to one another. In contrast, a "split-apart" red-green-red signal was 
detected in SNU16 cells, consistent with an inversion event occurring between these 
probes (Fig. 3.5A). 
 
Second, we directly confirmed a CD44/SLC1A2 genomic inversion in SNU16 cells using 
long-range genomic PCR, followed by end-sequencing of the PCR products. Using 
primers located to CD44 exon 1 and the SLC1A2 first intron (black arrows in Fig. 3.5A), 
we successfully PCR amplified and sequence validated a CD44/SLC1A2 inversion 
product in SNU16 fusion-positive cells but not in AGS cells (Fig. 3.5B). Taken 
collectively, these two alternative methods confirm the presence of a chromosomal 





















Figure 3.5. Confirmation of chromosomal inversion model of CD44-SLC1A2 gene 
fusion in SNU16 
A. Fiber-FISH analysis revealed an inversion of SLC1A2 to CD44 in SNU16 cells. Top, 
Rp1-68d18 biot covers CD44 (3' of intron 1) and SLC1A2 (3' of intron 1). Rp11-1148l23 
dig covers the 5' region of SLC1A2 intron 1 and upstream sequence. Bottom, Fiber-FISH 
images of control lymphoblast cell line CCL159 and fusion-positive SNU16 cells.  
B. Long-range PCR confirmed a chromosomal inversion of CD44-SLC1A2 in SNU16. 
Primers were targeted to CD44 exon 1 and the SLC1A2 first intron (black arrows in (A)). 







3.2.3 CD44-SLC1A2 protein expression 
Sequence analysis of the CD44-SLC1A2 fusion revealed two distinct protein translation 
patterns (Fig. 3.6A). First, translation initiating from an ATG site in CD44 exon 1 could 
produce a 65 aa protein, comprising 22 aa of CD44 and 43 aa of novel sequence. Second, 
protein translation might also initiate from an alternative ATG site in SLC1A2 exon 2, 
downstream of the fusion site. Notably, alternative SLC1A2 splice forms initiating from 
SLC1A2 exon 2 have been reported (see Ensembl EST database 
ENST00000395753/ENSP00000379102), consistent with protein translation initiating 
from the exon 2 ATG. Translation from this alternative ATG would produce a 565 amino 
acid truncated SLC1A2 protein that is 9 amino acids shorter than the full length form, but 
retaining all functionally relevant domains including transmembrane helices and 
symporter domains.   
 
We first conducted immunofluorescence assays on fusion positive SNU16 cells and 
fusion negative AGS cells using SLC1A2 antibodies. SNU16 cells expressed strong 
immunoreactivity to SLC1A2 antibodies in a strong membranous pattern. However, 
fusion negative AGS cells expressed cytoplasmic SLC1A2 (Fig. 3.6B). These results 
suggested that the CD44-SLC1A2 fusion might produce a SLC1A2 protein that is mostly 
localized in the membrane.   
 
To test if CD44-SLC1A2 produces a truncated SLC1A2 protein, we performed western 
blotting using anti-SLC1A2 antibodies on fusion positive and fusion negative GC cells. 
We specifically isolated proteins from the cell membrane. In SNU16 fusion-positive cells, 




SNU5 cells (Fig. 3.6C), consistent with translation initiating from SLC1A2 exon 2 in 
SNU16 cells. To further demonstrate that the alternative ATG in SLC1A2 exon 2 is 
capable of initiating protein translation, we cloned and expressed the full-length CD44-
SLC1A2 fusion gene in HFE145 gastric normal epithelial cells (Akhtar et al., 2001). 
Western blotting analysis confirmed expression of an immunoreactive SLC1A2 product 
in CD44-SLC1A2 transfected HFE145 cells of the expected size (Fig. 3.6D). This 
demonstrates that the alternative ATG in SLC1A2 exon 2 is sufficient to initiate 
translation. These findings suggest that the biological function of CD44-SLC1A2 is likely 







Figure 3.6. Protein expression of CD44-SLC1A2 
A. Predicted CD44-SLC1A2 protein translation patterns. Top left, translation initiates 
from an ATG site in CD44 exon 1, producing a 65aa protein. Top right, translation 
initiates from an alternative ATG site in SLC1A2 exon 2, producing a truncated SLC1A2 
protein of 565aa. Bottom, diagram illustrates the known protein domains of full length 
SLC1A2. The black arrow indicates the position of second protein translation initiation 
site. A truncated SLC1A2 protein beginning from exon 2 is predicted to encode all 
known functional domains.  
B. Immunofluorescence assays on fusion positive SNU16 cells and fusion negative AGS 
cells using SLC1A2 antibodies. SNU16 cells expressed strong membranous SLC1A2 




C. Western blot of fusion-positive SNU16 and fusion-negative AGS and SNU5 cells 
(membrane fractions). Top, anti-SLC1A2 antibodies. Bottom, -tubulin control.   
D. CD44-SLC1A2 ectopic expression in HFE145 normal gastric epithelial cell line. Top, 
CD44-SLC1A2 expression construct carrying a GFP tag. Arrow – promoter. ATG sites in 
CD44 exon 1 and SLC1A2 exon 2 are shown. Bottom, Immunoblotting with anti-SLC1A2 
antibodies. Vector-HFE145 cells transfected with vector control; Fusion- HFE145 cells 




3.3 Functional analysis of CD44-SLC1A2 fusion in GC cells 
 
3.3.1 Efficacy of the fusion-specific siRNA1  
To investigate the functional consequences of inhibiting CD44-SLC1A2 expression, we 
designed two customized siRNAs targeting the CD44-SLC1A2 fusion site to avoid 
confounding influences from wild-type CD44 and SLC1A2 transcripts. Treatment of 
SNU16 cells with 100 nM fusion specific siRNA1 successfully silenced CD44-SLC1A2 
expression after 48 hours, but did not discernibly alter the independent expression of 
CD44 or SLC1A2 (Fig. 3.7A). To confirm silencing at the protein level, we conducted 
immunofluorescence assays on both control and silenced SNU16 cells using SLC1A2 
antibodies. Untreated SNU16 cells expressed strong immunoreactivity to SLC1A2 
antibodies in a strong membranous pattern, which was significantly reduced by siRNA 
treatment (Fig. 3.7B). We further confirmed silencing at the protein level by western 




















Figure 3.7. CD44-SLC1A2 silencing by fusion-specific siRNA1 inhibits cellular 
proliferation, colony formation and invasion in SNU16 
A. CD44-SLC1A2 silencing by fusion-specific siRNA1 (CGCAGAUCGU 
GCCAACAAUUU) in SNU16. CD44-SLC1A2 expression was measured after 24h, 48h 
and 72h post siRNA treatment. CD44: wild-type CD44 expression. CD44 primers were 
designed to target exons 3-5. SLC1A2: wild-type SLC1A2 expression. SLC1A2 primers 
were designed to target exon 1. GADPH was used as a loading control.  
B. Immunofluorescence assays on both control and silenced SNU16 cells using SLC1A2 
antibodies. Untreated SNU16 cells expressed strong membranous expression of SLC1A2, 
which was significantly reduced by siRNA1 treatment. 
C. Western blotting in SNU16 with CD44-SLC1A2 silencing by CD44-SLC1A2 siRNA1.  
SLC1A2 protein levels were monitored using anti-SLC1A2 antibodies. Tubulin was used 
as a loading control. – and +: SNU16 cells transfected with scramble siRNA (-) and 




3.3.2 CD44-SLC1A2 silencing using siRNA1 reduces cancer cell proliferation, 
invasion, and colony formation 
We first silenced CD44-SLC1A2 in SNU16 and monitored proliferation changes. We 
observed a significant reduction in cell proliferation capacity upon siRNA1 treatment in 
SNU16 cells (Figure 3.7D, p=0.002). This result suggests that CD44-SLC1A2 may be 
important for cancer cell proliferation in GC. We also performed colony formation assay 
to assess the tumorigenicity of SNU16 upon CD44-SLC1A2 knockdown. We observed a 
potent inhibition of colony formation in fusion-silenced cells compared to controls 
(p=0.01, Figure 3.7E). We further conducted matrigel assays to investigate effects of 
CD44-SLC1A2 on cancer cell invasion. CD44-SLC1A2 -silenced SNU16 cells exhibited a 
decreased level of cell invasion compared with control cells (Figure 3.7F, p=0.0013), 





Figure 3.7. CD44-SLC1A2 silencing by fusion-specific siRNA1 inhibits cellular 
proliferation, colony formation and invasion in SNU16  
D-F. Functional effects of CD44-SLC1A2 silencing by fusion-specific siRNA1 in SNU16. 
D. SNU16 cells treated with CD44-SLC1A2 siRNA1 exhibited a significant decrease in 
proliferation rate (p=0.002) compared to scramble siRNA treated cells. Proliferation rates 
were measured at 24h, 48h and 72h post siRNA treatment. P value was calculated at T72 
using student‘s unpaired t-test. 
E. CD44-SLC1A2 silencing by fusion-specific siRNA1 significantly reduced 
tumorogenicity compared to scramble siRNA treated cells (p=0.01). P value was 
calculated using student‘s unpaired t-test. 
F. Cell invasion assays using SNU16 cells treated with scramble siRNA and CD44-
SLC1A2 siRNA1. Knockdown of CD44-SLC1A2 resulted in a significant reduction of 
invasion rate (p=0.0013) compared to scramble siRNA treated cells. P value was 




3.3.3 Efficacy of the fusion-specific siRNA2  
Due to the need for targeting a specific fusion site sequence, it was not possible to design 
a completely non-overlapping siRNA to confirm these results. However, when we used a 
second CD44-SLC1A2 targeting siRNA containing overlapping but distinct sequence, 
similar results were obtained as compared to fusion specific siRNA1. Treatment of 
SNU16 cells with 100 nM fusion specific siRNA2 successfully silenced CD44-SLC1A2 
expression after 72 hours, but did not alter the independent expression of CD44 or 
SLC1A2 (Fig. 3.8A). We also conducted immunofluorescence assays on both control and 
silenced SNU16 cells. Similar to fusion specific siRNA1 silencing, SNU16 cells 
transfected with scramble siRNA expressed strong immunoreactivity to SLC1A2 
antibodies in membrane, which was significantly reduced by siRNA treatment (Fig. 3.8B). 
Western blotting also confirmed silencing at the protein level by siRNA2 (Fig. 3.8C), 



















Figure 3.8. Silencing CD44-SLC1A2 with a second fusion specific siRNA inhibits 
cellular proliferation, invasion, and colony formation in SNU16 
A. Silencing of CD44-SLC1A2 by fusion-specific siRNA2 (GCACAUCGUGCC 
AACAAUAUU). Reduction of CD44-SLC1A2 expression was observed after siRNA2 
treatment, without impairing regular CD44 and SLC1A2 expression. CD44: wild-type 
CD44 expression. CD44 primers were designed to target exons 3-5. SLC1A2: wild-type 
SLC1A2 expression. SLC1A2 primers were designed to target exon 1. GADPH was used 
as a loading control.  
B. Immunofluorescence assays on both control and silenced SNU16 cells using SLC1A2 
antibodies. Untreated SNU16 cells expressed strong membranous expression of SLC1A2, 
which was significantly reduced by siRNA2 treatment. 
C. Western blotting analysis confirms knockdown of SLC1A2 protein expression in 
SNU16 (membrane fraction). SLC1A2 protein levels were monitored using anti-SLC1A2 
antibodies. Tubulin control confirmed equal amount of protein loading in both lanes. – 





3.3.4 CD44-SLC1A2 silencing using siRNA2 reduces cancer cell proliferation, 
invasion, and colony formation 
Similar to siRNA1 silencing, we observed a significant reduction in cell proliferation 
capacity upon siRNA2 treatment in SNU16 cells (Figure 3.8D, p<0.001), further 
suggesting that CD44-SLC1A2 may be important for cancer cell proliferation in GC. In 
addition, we observed a potent inhibition of colony formation in fusion-silenced cells 
compared to controls (p<0.001, Figure 3.8E). We also conducted matrigel assays to 
investigate effects of CD44-SLC1A2 on cancer cell invasion. CD44-SLC1A2 silenced 
SNU16 cells exhibited a decreased level of cell invasion compared with control cells 
(Figure 3.8F, p=0.04), suggesting a potential role for CD44-SLC1A2 in cell motility and 
invasion. Taken collectively, these results support a pro-oncogenic role for CD44-





Figure 3.8. Silencing CD44-SLC1A2 with a second fusion specific siRNA inhibits 
cellular proliferation, invasion, and colony formation in SNU16 
D-F. Functional effects of CD44-SLC1A2 silencing by fusion-specific siRNA2 in SNU16. 
D. SNU16 cells treated with CD44-SLC1A2 siRNA2 exhibit a significant decrease in 
proliferation rate (p<0.001) compared to scramble siRNA treated cells. Proliferation rates 
were measured at 24h, 48h and 72h post siRNA treatment. P value was calculated at T72 
using student‘s unpaired t-test. 
E. Colony formation assays revealed a reduction in numbers of colonies formed by fusion 
specific siRNA2 treatment compared to scrambled siRNA treatment (p=0.0007). P value 
was calculated using student‘s unpaired t-test. 
F. Knockdown of CD44-SLC1A2 using fusion siRNA2 also resulted in a significant 





3.3.5 Fusion specific siRNAs knockdown in fusion negative AGS cells 
To exclude the possibility of off target effects of fusion specific siRNAs, we transfected 
fusion negative AGS cells with the two customized fusion siRNAs. As expected, we 
observed no change in the expression of the wild type CD44 or SLC1A2 (Fig. 3.9A-B, 
left). In addition, no significant change in proliferation rate was observed after fusion 
specific siRNAs knockdown in AGS cells (Fig. 3.9A-B, right).  
 
3.3.6 Wild type SLC1A2 siRNAs knockdown in fusion negative AGS cells 
The observation that CD44-SLC1A2 produces an almost full-length SLC1A2 protein 
lacking only 9 amino acids raises the possibility that wild-type SLC1A2 might also be 
oncogenic. We tested this possibility by silencing wild-type SLC1A2 in AGS cells which 
are fusion negative. We designed customized SLC1A2 siRNA specifically targeting exon 
1 of SLC1A2 and also a non-overlapping wild type SLC1A2 siRNA. As shown in the 
Figure 3.10, silencing of wild-type SLC1A2 in AGS cells which are fusion negative with 
both siRNAs resulted in similar phenotypic effects comparable to CD44-SLC1A2 
silencing in SNU16 cells (Fig. 3.10). In this regard, CD44-SLC1A2 may be similar to 
oncogenic fusion genes such as IgH-Myc and TMPPRS2-ERG, whereby an essentially 









Figure 3.9. CD44-SLC1A2 silencing does not affect fusion negative AGS cells 
A. Left, expression of CD44-SLC1A2, SLC1A2 and CD44 after CD44-SLC1A2 siRNA1 
treatment in AGS fusion negative cells. CD44: wild-type CD44 expression. CD44 
primers were designed to target exons 3-5. SLC1A2: wild-type SLC1A2 expression. 
SLC1A2 primers were designed to target exon 1. GADPH was used as a loading control.  
Right, proliferation of AGS cells was not affected by fusion-specific siRNA1 silencing.  
B. Left, expression of CD44-SLC1A2, SLC1A2 and CD44 after CD44-SLC1A2 siRNA2 
treatment in AGS fusion negative cells. CD44 primers were designed to target exons 3-5. 
SLC1A2: wild-type SLC1A2 expression. SLC1A2 primers were designed to target exon 1. 
GADPH was used as a loading control. Right, proliferation of AGS cells was not affected 






Figure 3.10.  Reduction of cellular proliferation in fusion-negative AGS cells after 
silencing of wild-type SLC1A2  
A. Silencing of wild-type SLC1A2 in AGS cells using a siRNA targeting exon 1 of 
SLC1A2. Upper, reduction of SLC1A2 protein expression after SLC1A2 siRNA treatment. 
Tubulin control confirmed equal amount of protein loading in both lanes. Lower, AGS 
cell proliferation after treatment with a scrambled siRNA control or SLC1A2 exon 1 
siRNA. P value was calculated at T72 using student‘s unpaired t-test. 
B. AGS treated with a wild type SLC1A2 siRNA. Upper, reduction of SLC1A2 protein 
expression after SLC1A2 siRNA treatment. Lower, AGS cell proliferation after treatment 
with a scrambled siRNA control or SLC1A2 siRNA. P value was calculated at T72 using 






3.3.7 Overexpression of CD44-SLC1A2 to HFE145 cells  
To determine if CD44-SLC1A2 expression is sufficient to enhance various pro-oncogenic 
traits, we stably overexpressed CD44-SLC1A2 in HFE145 normal gastric cells. Compared 
to control cells, CD44-SLC1A2 expressing HFE145 cells exhibited enhanced cell 
proliferation (p=0.007) (Fig. 3.11A). Colony formation assays revealed a signification 
increase in numbers of colonies formed in cells transfected with CD44-SLC1A2 vector 
compared to vector only tranfected cells (p=0.02) (Fig. 3.11B).  Overexpression of 
CD44-SLC1A2 in HFE145 further resulted in a significant induction of invasion rate 
compared to vector tranfected cells (p=7.75E-05) (Fig. 3.11C). Taken collectively, these 
results suggest that CD44-SLC1A2 is likely required by GC cells to maintain several pro-







Figure 3.11.  Effects of CD44-SLC1A2 overexpression in HFE145 gastric normal 
epithelial cells 
A. HFE145 cells transfected with CD44-SLC1A2 expression vector exhibited a 
significant increase in proliferation rate (p=0.007) compared to vector only tranfected 
cells. Proliferation rates were measured at 24h, 48h and 72h post tranfection. P value was 
calculated at T72 using student‘s unpaired t-test. 
B. Colony formation assays revealed a signification increase in numbers of colonies 
formed in cells transfected with CD44-SLC1A2 vector compared to vector only tranfected 
cells (p=0.02).  P value was calculated using student‘s unpaired t-test. 
C. Overexpression of CD44-SLC1A2 in HFE145 also resulted in a significant induction 
of invasion rate compared to vector tranfected cells (p=7.75E-05). P value was calculated 




3.3.8 CD44-SLC1A2 silencing significantly reduces intracellular glutamate levels 
One possible mechanism by which CD44-SLC1A2 may contribute to tumor development 
is by facilitating glutamate uptake in GC cells. The function of SLC1A2 as a high-affinity 
glutamate transporter is intriguing, as previous studies have highlighted an important role 
for glutamate in cancer metabolism and signaling. Glutamate has been shown to regulate 
tumor growth and survival (Rzeski et al., 2002; Takano et al., 2001), and gastric tumors 
have been shown to contain higher glutamate levels compared to normal stomach (Okada 
et al., 1993). We hypothesized that expression of the CD44-SLC1A2 gene fusion might 
act to increase levels of intracellular glutamate in GC. To test this possibility, we 
measured levels of intracellular glutamate across the GC cell lines. A significantly higher 
basal glutamate level in CD44-SLC1A2 expressing SNU16 cells was observed compared 
to AGS cells (Fig. 3.12, p=0.009). Furthermore, after CD44-SLC1A2 siRNA treatment, 
SNU16 glutamate levels were significantly reduced compared to scramble siRNA control 
(Fig. 3.12, p=0.012). No significant effects were observed in the fusion siRNA treated 
AGS cells. This observation suggests that CD44-SLC1A2 may regulate intracellular 





















Figure 3.12.  CD44-SLC1A2 regulates intracellular glutamate levels 
Glutamate levels in GC cells before and after CD44-SLC1A2 siRNA treatment. CD44-
SLC1A2 positive SNU16 cells exhibited elevated intracellular glutamate levels compared 
to fusion negative AGS cells (p=0.009). Knockdown of CD44-SLC1A2 at T48 resulted in 
significant decrease of glutamate level in SNU16 cells (p=0.012), but not in AGS cells. 





3.3.9 CD44-SLC1A2 silencing sensitizes GC cells to chemotherapy 
Targeting glutamate metabolism in cancer cells has been shown to cause sensitization to 
pharmacologic treatment (Yang et al., 2009). To test if CD44-SLC1A2 silencing might 
sensitize GC cells to drug treatment, we treated control and CD44-SLC1A2 silenced 
SNU16 cells to increasing concentrations of cisplatin, a chemotherapy reagent commonly 
used in GC treatment. GI50s are computed, which is the drug concentration required to 
cause 50% growth inhibition. We found that SNU16 cells were significantly more 
sensitive to cisplatin after CD44-SLC1A2 siRNA treatment (p=1.11x10
-6
, Fig. 3.13A). 
The sensitization of CD44-SLC1A2 silenced cells appears to be specific to cisplatin, as no 
differences between the control and silenced cells were observed upon treatment with 5-






















Figure 3.13.  CD44-SLC1A2 sensitizes cells to Cisplatin chemotherapy but not 5-
Fluorouracil 
A. Cisplatin sensitivity of SNU16 cells with and without CD44-SLC1A2 siRNA silencing. 
SNU16 showed increased sensitivity to cisplatin after CD44-SLC1A2 siRNA treatment 
compared to scramble control (p=1.1X10
-6
 at 10uM cisplatin treatment).  P value was 
calculated at Concentration 10uM using student‘s unpaired t-test. 
B. 5-Fluorouracil sensitivity of SNU16 cells before and after CD44-SLC1A2 siRNA 
silencing. There was no significant change in sensitivity to 5-Fluorouracil after CD44-
SLC1A2 siRNA treatment compared to treatment with scramble siRNA control (p=0.33).  




3.4 CD44-SLC1A2 fusion in primary gastric tumors 
 
3.4.1 Screening of CD44-SLC1A2 fusion in breakpoint positive samples (Index 
samples) 
To test if CD44-SLC1A2 might be expressed in clinical specimens, we first assembled 
RNAs and screened two of the three original index cases exhibiting SLC1A2 genomic 
breakpoints (Fig. 3.2B). The third index tumor, GC20021048, had insufficient material 
available for analysis. Cloning and sequencing of the PCR products confirmed CD44-
SLC1A2 expression in tumor GC2000038, but not in corresponding matched normal 
tissue (Fig. 3.14A-B). This result demonstrates the CD44-SLC1A2 expression may occur 
















Figure 3.14. CD44-SLC1A2 expression in index (SLC1A2 breakpoint positive) 
primary GCs   
A. CD44-SLC1A2 RT-PCR on two index primary GCs (GC980417 and GC2000038) 
with SLC1A2 genomic breakpoints (see Fig. 1). GN2000038 is the matched normal 
sample to GC2000038. Fusion positive SNU16 was included as a positive control.  
B. Sequence of RT-PCR product in (A) revealed the CD44-SLC1A2 fusion junction in 




3.4.2 Recurrent CD44-SLC1A2 fusion in gastric tumor samples  
We screened CD44-SLC1A2 fusion in an independent panel of forty-three gastric tumors 
and matched gastric normal tissues. We performed CD44-SLC1A2 RT-PCR using 
forward primers to CD44 exon 1 and reverse primers to SLC1A2 exon 3. Out of 43 
tumors tested, two additional tumors amplified a PCR product of similar size to the 
CD44-SLC1A2 fusion transcript (Fig. 3.15A), and subsequent cloning and sequencing 
confirmed the expression of CD44-SLC1A2 in these tumors (Fig. 3.15B). Similar to the 
index samples, CD44-SLC1A2 is not expressed in corresponding matched normal 
samples (Fig. 3.15A, bottom), supporting the cancer specific nature of this fusion 
transcript. Subsequent cloning and sequencing of CD44-SLC1A2 in the fusion-positive 
tumors revealed that the fusion consistently involved the juxtaposition of CD44 exon 1 to 
SLC1A2 exon 2 (Fig. 3.15B). To rule out the possibility of contamination from SNU16, 
we further sequenced downstream of fusion transcript, and a nucleotide variant was 
identified in GC980390 which resulted in a silent mutation (Fig. 3.15C). This apparent 
requirement for precise joining may be because amongst the SLC1A2 exons, only exon 2 



























Figure 3.15. CD44-SLC1A2 expression in large cohort (unselected) of primary 
gastric tumors and their matched normals  
A. CD44-SLC1A2 RT-PCR on 43 gastric tumors and matched normal gastric tissues. Top, 
gastric tumor samples. Red stars highlight CD44-SLC1A2 expressing tumors (GC980390, 




B. Cloning and sequencing of CD44/SLC1A2 RT-PCR products from two fusion positive 
tumors (GC980390 and GC2000639) confirmed fusion between CD44 exon 1 and 
SLC1A2 exon 2. Black bars indicate the fusion junction.  
C. A silent mutation was found in CD44/SLC1A2 fusion transcript in GC980390. Top, 
CD44-SLC1A2 expression construct. Arrow–mutation site. Bottom, sequencing of 





3.4.3 Confirmation of CD44/SLC1A2 genomic inversions in fusion positive primary 
gastric tumors  
In our previous results (Fig. 3.5B), we used long-range PCR with genomic DNA, 
followed by end-sequencing of the PCR products, to confirm the presence of an 
intrachromosomal inversion in SNU16. To demonstrate that the genomic inversions may 
be one of the causal events leading to CD44/SLC1A2 fusion in primary tumors, we 
performed long-range PCR using the primers specifically directed against CD44 exon 1 
and the SLC1A2 intron 1, the same primer pairs used as in SNU16. The results showed 
the presence of CD44/SLC1A2 genomic inversions at the DNA level in the two fusion-
positive clinical specimens (GC980390 and GC2000038) (Fig. 3.16). Importantly, no 
such genomic inversion products were observed in the matched normal gastric samples, 














Figure 3.16. Long-range genomic PCR analysis in fusion positive gastric tumor 
tissues  
Long-range PCR confirmed a chromosomal inversion of CD44-SLC1A2 in two fusion 
positive gastric tumors (GC2000038 and GC980390). GN2000038, GN980390 and 
GN2000639 are matched gastric normal controls. SNU16 was used as a positive control. 




3.4.4 Tumors expressing high SLC1A2 levels are associated with CD44-SLC1A2 
positivity 
The CD44 gene is both activated by Wnt signaling and repressed by p53, two common 
cancer-related pathways. As such, CD44 is highly expressed in many cancers including 
GC (Kim et al., 2009). Therefore, one consequence of the CD44-SLC1A2 fusion might be 
to place SLC1A2 under the regulatory control of CD44 promoter elements, causing high 
levels of SLC1A2 expression in tumors. This model predicts that tumors expressing high 
SLC1A2 levels may also tend to be CD44-SLC1A2 positive. To explore this possibility, 
we queried a previously described gene expression database of 197 gastric cancers to 
identify tumors expressing high SLC1A2 levels (Ooi et al., 2009). We screened fifteen 




SLC1A2 overexpressing tumors for CD44-SLC1A2 
expression. Among the fifteen tumors, five GCs expressed the CD44-SLC1A2 fusion 
transcript (Fig. 3.17, blue crosses), and none of the matched adjacent normal tissues 
expressed CD44-SLC1A2 (Fig. 3.17). Thus, while the rate of CD44-SLC1A2 positivity in 
an unselected patient cohort is low (1-2%), the CD44-SLC1A2 positivity rate is elevated 
in this selected subpopulation (33%, 5 out of 15 tumors).  This result is consistent with 
the CD44-SLC1A2 fusion causing the transcriptional upregulation of SLC1A2. In CD44-
SLC1A2 negative tumors, high SLC1A2 levels may be attributed to alternative 
mechanisms, such as focal genomic amplification, fusion to other partners, and EGF or 




















Figure 3.17. CD44-SLC1A2 positive tumors are associated with high SLC1A2 
expression 
Graph, x-axis - 197 GCs sorted by levels of SLC1A2 expression. Y-axis: Log 
transformed gene expression data were median-centered. The top 15% of high SLC1A2 
expressing tumors are shown in red. Inset, RT-PCR screening of CD44-SLC1A2 in the 
top 15% of high SLC1A2-expressing GCs. GADPH was used as a loading control. 
Samples expressing CD44-SLC1A2 are highlighted using blue crosses. SNU16 cells (S16) 
were included as a positive control. The smaller band of 200bp was sequenced and 
identified to be non-specific (ns). CD44-SLC1A2 RT-PCR analysis of the matching 15 




3.4.5 Glutamate levels in primary gastric tumors  
In many cancers, glutamate and its related amino acid glutamine function as important 
amino acids regulating tumor growth and survival (Rzeski et al., 2002; Takano et al., 
2001), and gastric tumors have been shown to contain higher glutamate levels compared 
to normal stomach tissues (Okada et al., 1993). Previously, we have shown that CD44-
SLC1A2 silencing significantly reduces intracellular glutamate levels in gastric cancer 
cells (Fig. 3.11). Next, to assess the levels of glutamate in our in-house primary GCs, we 
used the glutamate assay to measure glutamate levels in 20 pairs of matched tumor and 
normal pairs. Significantly elevated levels of glutamate were detected in primary tumors 
compared to matched normal stomach controls (n=20, p=0.038, paired t-test) (Fig. 3.18), 



















Figure 3.18. Glutamate levels in primary GCs  
Glutamate levels were significantly higher in gastric tumor tissues compared to their 
matched normals (p=0.038). x-axis: 20 cancer/normal pairs (Gastric cancer – black, 





3.4.6 CD44-SLC1A2 expression can occur independently of 11p13 amplification  
Although CD44-SLC1A2 was initially identified in tumors exhibiting 11p13 
amplification (Fig. 3.2B), 11p13 amplification may not be essential for CD44-SLC1A2 
fusion expression. To investigate the relationship between 11p13 genomic amplification 
and CD44-SLC1A2 expression, we analysed seven fusion positive tumors using 
Affymetrix SNP6 arrays. Of seven fusion-positive tumors, two tumors (GC980390 and 
GC990172) exhibited evidence of 11p13 genomic amplification, while the other five did 
not (Fig. 3.19). This finding demonstrates that CD44-SLC1A2 expression may be 
observed in tumors independent of 11p13 genomic amplification. Further supporting the 
notion that 11p13 amplification and CD44-SLC1A2 gene fusion are distinct events, a 
comparison of CD44 and SLC1A2 expression levels across 45 gastric tumors, including a) 
11p13 non-amplified samples (32 samples); b) 11p13 amplified but fusion-negative 
samples (6 samples), and c) CD44-SLC1A2 fusion positive samples (7 samples) revealed 
that high SLC1A2 expression levels may be more strongly associated with fusion-events 









Figure 3.19. 11p13 copy number status in CD44-SLC1A2 expressing samples 
 
Seven CD44-SLC1A2 expressing tumors were analyzed for 11p13 copy number 
amplification using Affymetrix SNP6 arrays. The X-axis indicates genomic position and 
the y-axis is the log transformed copy number data. Each blue dot represents a SNP array 
probe. Segmented copy number data are plotted as horizontal black lines. The CD44 and 
SLC1A2 gene region is highlighted as a red rectangle 
 
(A) Two fusion-positive samples (GC980390 and GC990172) exhibiting 11p13 
amplification. 
 





































3.4.7 Impact of 11p13 amplifications and CD44-SLC1A2 fusions on SLC1A2 and 
CD44 expression  
We compared CD44 and SLC1A2 expression levels across 45 gastric tumors, including a) 
11p13 non-amplified samples (32 samples); b) 11p13 amplified but fusion-negative 
samples (6 samples), and c) CD44-SLC1A2 fusion positive samples (7 samples). The rate 
of 11p13 amplification in this series (~17%) is similar to frequencies previously reported 
in the literature (Fukuda et al., 2000). It is important to note that in this experiment, the 
expression measurements were inferred using U133P2 Affymetrix microarray probes, 
which target the 3‘ ends of genes. Compared to non-amplified samples, fusion positive 
samples exhibited significantly increased 3‘ SLC1A2 gene expression (p=0.004), but 
11p13 amplified samples did not (p=0.86) (Fig. 3.20A). These findings suggest that high 
SLC1A2 expression levels may be driven more by fusion-events rather than generalized 
11p13 amplification The one exception was a sample with a high-level focal 11p13 
amplification (GC980417) – in this tumor, SLC1A2 was highly expressed (Fig. 3.20A). 
Intriguingly, unlike SLC1A2, a very different scenario was observed for CD44. 
Specifically, while CD44 3‘ transcripts were significantly overexpressed in 11p13 
amplified tumors (p=0.016), they were significantly underexpressed in fusion positive 
tumors (p=0.006) (Fig. 3.20B). We postulate that this latter finding may be due to the 
CD44/SLC1A2 genomic inversion decoupling the 3‘ end of the CD44 gene (the region 
detected by the Affymetrix array) from the endogenous CD44 promoter. Additional 
evidence of this decoupling was obtained in a real-time PCR analysis measuring SLC1A2 




CD44-SLC1A2 fusion) was not observed to be highly expressed relative to non-amplified 







Figure 3.20. CD44 and SLC1A2 expression levels of 11p13 non-amplified, 11p13 
amplified, and fusion positive samples 
A-B. CD44 and SLC1A2 expression in 45 gastric tumor samples profiled on both gene 
expression and SNP microarrays. Of these 45, 32 samples are 11p13 non-amplified (blue), 
6 samples are 11p13 amplified but fusion-negative (yellow), and 7 samples are CD44-
SLC1A2 fusion positive (red). Significant p-values (p<0.05, Student‘s t-test) are shown in 
red. Whiskers represent the range of data. Borders of the box indicate 25
th
 percentile and 
75
th
 percentile of the data respectively. The bar inside each box indicate average value of 
the data in each category.  
A. SLC1A2 gene expression measured using Affymetrix U133 plus probe 225491_at. 




to non-amplified samples (p=0.004), but 11p13 amplified samples do not (p=0.86). The 
blue arrow highlights one 11p13 amplified sample (GC980417) with a high-level focal 
amplification in the CD44/SLC1A2 gene region, suggesting that in some cases 11p13 
amplification can drive increased SLC1A2 gene expression.  
B. CD44 gene expression measured using Affymetrix U133 plus probe 212063_at. 
11p13-amplified samples showed significantly increased CD44 expression compared to 
non-amplified samples (p=0.016) but fusion positive samples showed a significantly 
decreased level of CD44 expression (p=0.0059), consistent with the CD44/SLC1A2 
inversion event decoupling the wild-type CD44 gene from its endogenous promoter.  
C-D. Real-time PCR analysis of CD44-SLC1A2 expression (targeting the fusion junction), 
and SLC1A2 (targeting SLC1A2 exon 1). The tumors were stratified into 3 groups. Group 
1: T1-3, 11p13 non-amplified and fusion negative; Group 2: T4-6, 11p13 amplified and 
fusion negative; and Group 3: T7-9, 11p13 non-amplified but fusion positive. AGS 
(fusion-negative) and SNU16 (11p13 amplified, fusion positive) were also included. All 
readings were normalized against a GADPH housekeeping control. Each data point 
represents the average of two independent experiments.  
C. CD44-SLC1A2 fusion expression. Only Group 3 fusion-positive tumors and SNU16 
cells were observed to express CD44-SLC1A2.  
D. SLC1A2 exon 1 expression. 11p13-amplified samples were observed to express high 
levels of SLC1A2 exon 1, consistent with these samples exhibiting ―copy number driven‖ 
expression. In contrast, SLC1A2 exon 1 was not highly expressed in 2 out of 3 fusion 
positive samples, consistent with the high levels of 3‘ SLC1A2 transcript in these samples 




3.4.8 Unsupervised clustering of GC expression profiles reveals clustering of 
SLC1A2-high expressing tumors 
Next, we explored if SLC1A2-high expressing tumors might be associated with any 
distinct clinicopathogic traits. To study whether the SLC1A2-high expressing tumors 
exhibit molecular similarity and whether the fusion subclass emerges as a discrete subset, 
we performed an unsupervised clustering analysis of the 197 gastric tumors. The results 
revealed that a subclass of high SLC1A2-expressing tumors tended to cluster together, 
suggesting that high SLC1A2 expression may define a distinct molecular subgroup of GC 
(Fig. 3.21). To identify predominant biological themes associated with this molecular 
subgroup, we performed gene ontology analysis on a 710-gene ‗SLC1A2 signature‘, 
generated by comparing the top 15% of SLC1A2 high-expressing tumors against the 
bottom 15% (Wilcoxon signed ranked test, FDR =0.005). Genes expressed in SLC1A2 
high expressing tumors were associated with ribosomal biosynthesis and protein 
translation (corrected p=5.12x10
-33
; Fisher test, Table 3.2). These results suggest that a 
subgroup of tumors expressing high SLC1A2 levels, either by CD44 fusion or alternative 








Figure 3.21. Unsupervised clustering of GC expression profiles reveals clustering of 
SLC1A2-high expressing tumors 
197 GC gene expression profiles were clustered using an unsupervised hierarchical 
clustering algorithm. Samples with high SLC1A2 expression (top 15%) were indicated 
with a ‗+‘. A subgroup of the high SLC1A2 expressing tumors were observed to cluster 





Table 3.2 : Gene ontology analysis of SLC1A2-high expressing tumors 
 
 

















Ribosome 32 9.01 1.43E-
35 
5.12E-33 




































































































































Category – Database; Term - Enriched ontology term;  Count - Number of genes 
overlapping with the SLC1A2 signature; % - percentage of overlapping genes from input 
signature list; P-value - Modified Fisher exact test pvalue; Benjamini - corrected p value 






Chapter IV: Discussion 
The cancer-specific nature of fusion genes have earned them an important place in many 
translational cancer research applications, including molecular subtyping, monitoring for 
disease relapse, and as drug targets. In pediatric ALL, expression of AML-ETO and PML-
RAR are routinely used to diagnose particular clinical subtypes (Ghaffari et al., 2006). 
The treatment of CML has been revolutionized by imatinib, an inhibitor of the BCR-ABL 
fusion gene (Deininger et al., 2005). Along with AGTRAP-BRAF fusions (Palanisamy et 
al., 2010), CD44-SLC1A2 represents another recurrent gene fusion identified in a major 
GI cancer, providing further evidence for the existence of this important class of 
molecular aberrations in GI malignancies.  
 
In this study, we used Genomic Breakpoint Analysis (GBA) to uncover the existence of 
CD44-SLC1A2 gene fusions in GC. Although our starting microarray data set of GC 
CNAs is similar to data sets used in regular array-based Comparative Genomic 
Hybridization (aCGH) studies (Niini et al., 2010), our analytical strategy differs 
fundamentally from aCGH. Specifically, in conventional aCGH, attention is primarily 
focused on genes residing in the central regions of amplicons, while in our approach, 
amplicon boundaries and edges assume greater relevance. Notably, while GBA has been 
previously used for fusion gene discovery in leukemia (Kawamata et al., 2008; Mullighan 
et al., 2007), our study demonstrates that this approach can also highlight potential fusion 





Amongst genes exhibiting genomic breakpoints, we prioritized genes for study based on 
their rates of recurrence in multiple samples and the specificity of the breakpoints. Using 
these two criteria, we noted that only a minor portion of candidate genes exhibited 
recurrent breakpoints (N>=2, Table 3.1). In addition, for the majority of genes exhibiting 
genomic breakpoints in multiple samples (eg CRKRS, TTC25), the breakpoints were 
randomly scattered throughout the gene body consistent with a random breakage model 
of chromosomal amplification. SLC1A2 was nominated for further experimental studies 
as four GCs out of 133 exhibited genomic breakpoints specifically localized to the 5' 
region of the SLC1A2 gene (Fig. 3.2 B).  
 
GBA does come with a few caveats, as fusion events arising from balanced chromosomal 
rearragements would not alter overall copy number levels and are unlikely to be detected. 
Whether the fusion genes identified by breakpoint analysis are similar or different to 
those identified by other methods such as COPA, transcriptome sequencing, and genomic 
paired-end sequencing is yet unclear (Bignell et al., 2007; Rubin and Chinnaiyan, 2006). 
Applying these distinct discovery methods on a common set of cancer samples would 
prove useful to clarify the specific pros and cons of each approach. However, GBA has 
the advantage of being readily applicable to array-CGH data, for which there are 
numerous large scale data sets available in the public domain (Beroukhim et al., 2010). 
Revisiting these data sets may identify additional genes recurrently targeted by genomic 





Chromosomal amplification events are often associated with complex patterns of local 
genome rearrangement (Bignell et al., 2007), and the CD44-SLC1A2 fusions were 
identified by tumors and cell line exhibiting SLC1A2 genomic breakpoints in regions of 
generalized 11p13 amplification (Fig. 3.2B). SKY and FISH analysis confirmed 
chromosomal rearrangement associated with 11p13 amplification in SNU16 (Fig. 3.3). 
Given the close genomic proximity of CD44 and SLC1A2, it is likely that the CD44-
SLC1A2 fusion is caused by a paracentric inversion resulting in the physical fusion of the 
CD44 upstream region to the SLC1A2 gene (Fig. 3.4C). Supporting this model, genome 
rearrangements and inversions within the CD44/SLC1A2 region in SNU16 cells and 
fusion positive tumors were demonstrated using fiber-FISH and high resolution long-
range PCR (Fig. 3.5, Fig. 3.16). Emerging evidence indicates that genes in close 
proximity may represent favorable targets for gene fusion events in cancer. For example, 
in prostate cancer the tendency of TMPRSS2 to fuse with ERG rather than ETV1 or ETV4, 
when all three genes encode ETS transcription factors, is likely due to TMPRSS2 lying 
only 3 Mb away from ERG on Chr 21, with both genes being brought together in close 
proximity due to androgen receptor mediated interactions (Lin et al., 2009; Mani et al., 
2009). Likewise, in breast cancer, production of the BCAS3/BCAS4 fusion gene is also 
likely facilitated by local genomic rearrangements affecting both genes on Chromosome 
17 (Bärlund et al., 2002). 
 
The identification of SLC1A2, a glutamate transporter, as a fusion gene participant is 
notable. To date, the vast majority of known oncogenic fusion events have largely 




al., 1982; Edwards, 2010; Ghaffari et al., 2006; Rabbitts and Boehm, 1991). The 
discovery of CD44-SLC1A2 raises the intriguing possibility that oncogenic gene fusions 
may also target genes involved in cancer metabolism. Importantly, the notion that 
glutamate is relevant for cancer development is not without precedent. Indeed, a 
substantial body of evidence has implicated glutamate and glutamine as a critical amino 
acid necessary for the maintenance and elaboration of many cancer-specific traits 
(DeBerardinis and Cheng, 2010; Medina et al., 1992). For example, glutamate and 
glutamine have been shown to regulate tumor growth and control oncogenic signals such 
as mTOR (Nicklin et al., 2009; Rzeski et al., 2002; Takano et al., 2001). The requirement 
of cancer cells for glutamate may also be related to the Warburg effect - a universal 
feature of cancer cells where they exhibit overactive glycolysis due to a deficiency in 
channeling glycolytic metabolites into the TCA cycle for ATP generation. Besides 
glycolysis, glutamate may provide cancer cells with an alternative route of ATP 
production since intracellular glutamate and glutamine can also be converted into alpha-
ketoglutarate, a TCA cycle intermediate (Dang, 2010).  
 
Our study also suggests that CD44-SLC1A2 may function to facilitate glutamate 
accumulation in GC cells. The CD44-SLC1A2 gene fusion is predicted to produce a 
slightly truncated SLC1A2 protein that retains most of the key protein domains required 
for glutamate transporter fusion, and protein immunoflouresence studies revealed high 
SLC1A2 immunoreactivity at the cell membrane in SNU16 cells, consistent with its role 
as a glutamate transporter (Fig. 3.6). Moreover, silencing of CD44-SLC1A2 reduced 




several pro-oncogenic phenotypes such as cellular proliferation, invasion and colony 
formation (Fig. 3.7, Fig. 3.8). Glutamate levels have been shown to be elevated in many 
cancers, and in our study we confirmed that glutamate levels are also elevated in gastric 
tumors compared to normal stomach, consistent with a previous report (Okada et al., 
1993) (Fig. 3.18).  
 
Our ability to study the effects of endogenous CD44-SLC1A2 inhibition was limited to 
SNU16 cells since this is the only fusion-positive GCCL. Therefore, we have further 
demonstrated a pro-oncogenic role for CD44-SLC1A2 in two ways. First, because CD44-
SLC1A2 is predicted to produce a slightly truncated but almost full-length SLC1A2 
protein, it is possible that wild-type SLC1A2 should exhibit pro-oncogenic effects. We 
tested this possibility by silencing wild-type SLC1A2 in AGS cells which is fusion 
negative. As shown in Figure 3.10, we observed significant phenotypic effects in the 
AGS cells, similar to CD44-SLC1A2 knockdown in SNU16 fusion-positive cells. These 
results suggest a pro-oncogenic role for both CD44-SLC1A2 and SLC1A2. In this regard, 
CD44-SLC1A2 is similar to other recognized fusion genes such as IgH-Myc and 
TMPPRS2-ERG, where an essentially wild-type pro-oncogenic protein is placed under 
the control of a strong transcriptional promoter. Second, we ectopically expressed CD44-
SLC1A2 in HFE145 gastric epithelial cells (Fig. 3.12). Compared to control cells, CD44-
SLC1A2 overexpressing HFE145 cells demonstrated enhanced cellular proliferation, 
colony formation, and invasion, once again supporting a pro-oncogenic role for CD44-





Beyond its effects in cancer development, targeting CD44-SLC1A2 in fusion-positive 
tumors may also represent a promising avenue for sensitizing GCs to commonly used 
standard-of-care chemotherapies, since silencing CD44-SLC1A2 was sufficient to cause a 
significant sensitization of GC cells to cisplatin in vitro (Fig. 3.13). It will be interesting 
to evaluate the potential of CD44-SLC1A2 as a drug target, and determining exactly how 
this gene fusion, and possibly other glutatmate-related transporters, may contribute to GC 
development by establishing a metabolic environment favouring oncogenesis.  
 
To extend this study from in vitro to in vivo, we also screened CD44-SLC1A2 fusion in 
primary gastric tumors. The initial rate of CD44-SLC1A2 positivity in an unselected GC 
patient cohort was low (2/43) (Fig. 3.15), this frequency was markedly increased when 
analysis was confined to a specific patient sub-population (tumors with high SLC1A2 
expression) (Fig. 3.17). We believe that this result underscores the reality that most solid 
epithelial cancers are likely to comprise a heterogeneous collection of distinct biological 
subtypes, each with distinctive patterns of genetic aberrations and oncogenic pathway 
activity.  It is worth noting that the issue of tumor heterogeneity has not been explicitly 
considered in many previous cancer genome studies (Wood et al., 2007), and our results 
suggest that this issue should be incorporated in future fusion gene discovery efforts. 
 
The absolute rate of CD44-SLC1A2 positivity appeared to be relatively low in this study, 
however analyses of larger GC patient cohorts will be required to determine the true 
CD44-SLC1A2 positivity rate. Nevertheless, we note that even low frequency events in 




5%) (Soda et al., 2007) and RAF fusions in gastric, melanoma and prostate cancers 
(Palanisamy et al., 2010). 
 
We cloned and sequenced the CD44-SLC1A2 fusion transcript from 6 fusion-positive 
tumors, including SNU16 cells. In all cases, the fusion involved a juxtaposition of CD44 
exon 1 to SLC1A2 exon 2. This recurrent juxtaposition is not unexpected, since amongst 
the SLC1A2 exons, only SLC1A2 exon 2 possesses a suitable alternative start ATG to 
initiate translation of a near complete SLC1A2 protein. This information further supports 
the functional significance of the CD44-SLC1A2 fusion. We identified genetic variations 
in the CD44-SLC1A2 sequences from different fusion-positive cases, demonstrating that 
they are distinct entities. These sequence polymorphisms, occurring in SLC1A2 exon 4 
corresponding to a silent T/C variant, were confirmed by resequencing both strands (Fig. 
3.15C). These findings collectively indicate that CD44-SLC1A2 expression is recurrent.  
 
Most of the SLC family gene fusions identified to date have involved the SLC gene at the 
5' end of the fusion, such as SLC45A3-BRAF in prostate cancer and SLC34A2-ROS1 in 
non-small-cell lung cancer. To determine if there is a productive 3' partner for SLC1A2, 
we performed 3‘ RACE from exon1 of SLC1A2 in SNU16 cells. However, only wild-
type SLC1A2 products were detected downstream from SLC1A2 exon 1. In addition, due 
to limited tissue availability, we could not perform 3‘ RACE in primary tumors. Thus, at 
this point, we are not able to conclude that the SLC1A2 3‘ end is involved in another 
productive fusion. However, 66% of tumors expressing high SLC1A2 levels did not 




possible that SLC1A2 expression might be driven by fusion to other upstream partners 
besides CD44 or due to transcriptional induction of SLC1A2 by EGF or mTOR/Akt 
signaling (Wu et al., 2010; Zelenaia et al., 2000). More work will be required to clarify if 
SLC1A2 possesses other fusion partners in GC. Similar examples of such ―promiscuous‖ 
fusion genes have also been reported for ERG in prostate cancer and EWS in Ewing 
sarcoma (Sorensen et al., 1994). 
 
To determine the association between 11p13 genomic amplification and CD44-SLC1A2 
fusion expression, we analyzed a panel of fusion positive tumors using Affymetrix SNP6 
arrays, which enabled DNA copy number measurements at more than 1.8 million markers 
across the genome. Of seven fusion-positive cases, two tumors exhibited evidence of 
11p13 genomic amplification, while the other five did not (Fig. 3.19). This finding 
demonstrates that CD44-SLC1A2 expression may be observed in tumors independently of 
11p13 genomic amplification, suggesting that it is not a mere epiphenomenon of 11p13 
amplification.  
 
In addition, we investigated the influence of 11p13 amplification and CD44-SLC1A2 
fusion on CD44 and SLC1A2 expression. Specifically, we compared CD44 and SLC1A2 
expression levels across 45 gastric tumors, including a) 11p13 non-amplified samples (32 
samples); b) 11p13 amplified but fusion-negative samples (6 samples), and c) CD44-
SLC1A2 fusion positive samples (7 samples) (Fig. 3.20). We noted that the rate of 11p13 
amplification in this series (~17%) is similar to frequencies previously reported in the 




samples exhibited significantly increased SLC1A2 gene expression, but 11p13 amplified 
samples did not. In contrast, while CD44 3‘ transcripts were significantly overexpressed 
in 11p13 amplified tumors, these transcripts were significantly underexpressed in fusion 
positive tumors (Fig. 3.20). The latter finding is consistent with the CD44/SLC1A2 
genomic inversion decoupling the 3‘ end of the CD44 gene body (the region detected by 
the Affymetrix array) from the endogenous CD44 promoter. Further evidence of this 
decoupling was obtained in a real-time PCR analysis measuring SLC1A2 exon 1, which is 
not part of the CD44-SLC1A2 fusion. Unlike the 3‘ SLC1A2 transcripts, SLC1A2 exon 1 
was not observed to be highly expressed relative to non-amplified samples. These 
findings suggest that high SLC1A2 expression levels are driven more by fusion-events 
rather than general 11p13 amplification (Fig. 3.20).   
 
In an unsupervised clustering analysis of 197 gastric tumors, we found that a subgroup of 
SLC1A2 high-expressing tumors tended to cluster to one another, suggesting that this 
subgroup of SLC1A2-expressing tumors may represent a discrete molecular subclass (Fig. 
3.21). Using pathway analysis, we also found that genes upregulated in SLC1A2-high 
expressing tumors were significantly enriched in genes related to ribosomal function and  
protein translation (Table 3.2), further supporting the notion that SLC1A2-high expressing 





Chapter V: Conclusion 
We believe that our study will be of great interest to the GC community, as it represents 
one of the first recurrent fusion transcripts identified in this disease (and for that matter 
any common gastrointestinal cancer). Although previous reports have used GBA to 
identify fusion genes in leukemia and other haematopoietic malignancies, we are the first 
to show that such a genomic approach can be successfully applied to discover fusion 
genes in a solid epithelial cancer. In addition, CD44-SLC1A2 represents a novel example 
of a fusion gene where the fusion partner (SLC1A2) may play a direct role in cancer 
metabolism, which is different from previously-described fusion genes that have largely 
involved signalling proteins (kinases) or transcription factors.  
 
As this is the first report that GBA may be successfully applied to discover fusion genes 
in solid epithelial cancer, such strategy can be used in future to identify fusion genes in 
other types of solid cancer. In addition, targeting CD44-SLC1A2 in fusion-positive 
tumors may also represent a promising avenue for sensitizing GCs to commonly used 
standard-of-care chemotherapies, since silencing CD44-SLC1A2 was sufficient to cause a 
significant sensitization of GC cells to cisplatin in vitro. It will be interesting to evaluate 
the potential of CD44-SLC1A2 as a drug target. We also showed that patients with tumors 
expressing high SLC1A2 levels may represent a distinct molecular subgroup. Thus, 
CD44-SLC1A2 and/or high SLC1A2 levels could be used as a diagnostic biomarker.  
 
As a cell membrane-bound receptor, CD44-SLC1A2 may prove amenable to targeting 




in treating GC patients. As SLC1A2 has been extensively studied in Central Nervous 
System (CNS) associated diseases, and there are numerous glutamate inhibitors available 
in the market, it would be interesting to test the effects of different glutamate inhibitors to 
GC cell lines.  
 
Interestingly, we have also identified that several of the CD44-SLC1A2 positive GCs in 
our study also exhibited focal amplifications in genes specifically related to 
RTK/RAS/MAPK signaling, including SNU16 (FGFR2), GC2000114 (MET), 
GC2000639 (KRAS), and GC980390 (ERBB2) (Data not shown). It is thus possible that 
CD44-SLC1A2 may collaborate with these canonical oncogenes to facilitate MAPK 
signalling in gastric cancer cells. Our preliminary study has shown that siRNA specific 
knockdown of CD44-SLC1A2 decreased FGFR2 protein level in SNU16 (Data not 
shown). Taken collectively, one of the future perspectives would be to further investigate 
the association between CD44-SLC1A2 and MAPK pathway in GC. 
 
The absolute rate of CD44-SLC1A2 positivity appeared to be relatively low in this study. 
On the diagnostic front, we are very interested in validating these findings in larger 
patient cohorts, both to assess the true frequency of this fusion gene, and also to 
investigate if there are any clinical or pathologic associations, such as survival rates, 
associated with CD44-SLC1A2 positivity.  
 
In addition, 66% of tumors expressing high SLC1A2 levels did not appear to express 




expression might be driven by fusion to other upstream partners besides CD44.  More 
work will be required to clarify if SLC1A2 possesses other fusion partners in GC.  
 
To our knowledge, CD44-SLC1A2 represents one of the first recurrent gene fusions 
identified in a major GI cancer, providing evidence for the existence of this important 
class of molecular aberrations in GI malignancies. Our results thus strongly warrant 
additional efforts to identify additional fusion genes in gastrointestinal cancer. For 
example, transcriptome sequencing approaches have recently identified rare AGTRAP-
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